A	O
mutation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
primary	O
cortisol	O
resistance	O
.	O

The	O
precise	O
molecular	O
abnormalities	O
that	O
cause	O
primary	O
cortisol	O
resistance	O
have	O
not	O
been	O
completely	O
described	O
.	O

In	O
a	O
subject	O
with	O
primary	O
cortisol	O
resistance	O
we	O
have	O
observed	O
glucocorticoid	B-protein
receptors	I-protein
(	O
hGR	B-protein
)	O
with	O
a	O
decreased	O
affinity	O
for	O
dexamethasone	O
.	O

We	O
hypothesize	O
that	O
a	O
mutation	O
of	O
the	O
hGR	B-protein
glucocorticoid-binding	I-protein
domain	I-protein
is	O
the	O
cause	O
of	O
cortisol	O
resistance	O
.	O

Total	O
RNA	O
isolated	O
from	O
the	O
index	O
subject	O
's	O
mononuclear	B-cell_type
leukocytes	I-cell_type
was	O
used	O
to	O
produce	O
first	O
strand	O
hGR	B-DNA
cDNAs	I-DNA
,	O
and	O
the	O
entire	O
hGR	B-DNA
cDNA	I-DNA
was	O
amplified	O
in	O
segments	O
and	O
sequenced	O
.	O

At	O
nucleotide	O
2	O
,	O
317	O
we	O
identified	O
a	O
homozygous	O
A	O
for	O
G	O
point	O
mutation	O
that	O
predicts	O
an	O
isoleucine	O
(	O
ATT	O
)	O
for	O
valine	O
(	O
GTT	O
)	O
substitution	O
at	O
amino	O
acid	O
729	O
.	O

When	O
the	O
wild-type	B-protein
hGR	I-protein
and	O
hGR-Ile	B-protein
729	I-protein
were	O
expressed	O
in	O
COS-1	B-cell_line
cells	I-cell_line
and	O
assayed	O
for	O
[	O
3H	O
]	O
-Dexamethasone	O
binding	O
,	O
the	O
dissociation	O
constants	O
were	O
0.799	O
+/-	O
0.068	O
and	O
1.54	O
+/-	O
0.06	O
nM	O
(	O
mean	O
+/-	O
SEM	O
)	O
(	O
P	O
<	O
0.01	O
)	O
,	O
respectively	O
.	O

When	O
the	O
wild-type	B-protein
hGR	I-protein
and	O
hGR-Ile	B-protein
729	I-protein
were	O
expressed	O
in	O
CV-1	B-cell_line
cells	I-cell_line
that	O
were	O
cotransfected	O
with	O
the	O
mouse	B-DNA
mammary	I-DNA
tumor	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
fused	O
to	O
the	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
,	O
the	O
hGR-Ile	B-protein
729	I-protein
conferred	O
a	O
fourfold	O
decrease	O
in	O
apparent	O
potency	O
on	O
dexamethasone	O
stimulation	O
of	O
CAT	B-protein
activity	O
.	O

The	O
isoleucine	O
for	O
valine	O
substitution	O
at	O
amino	O
acid	O
729	O
impairs	O
the	O
function	O
of	O
the	O
hGR	B-protein
and	O
is	O
the	O
likely	O
cause	O
of	O
primary	O
cortisol	O
resistance	O
in	O
this	O
subject	O
.	O

A	NULL
Mutation	NULL
of	NULL
the	NULL
Glucocorticoid	NULL
Receptor	NULL
in	NULL
Primary	NULL
Cortisol	NULL
Resistance	NULL
Diana	NULL
M.	NULL
Maichoff	NULL
,	NULL
*	NULL
Adam	NULL
Brufsky	NULL
,	NULL
*	NULL
George	NULL
Reardon	NULL
,	NULL
}	NULL
Patrick	NULL
McDermott	NULL
,	NULL
*	NULL
Emmanuel	NULL
C.	NULL
Javier	NULL
,	NULL
*	NULL
Claes-Hakan	NULL
Bergh	NULL
,	NULL
*	NULL
David	NULL
Rowe	NULL
,	NULL
``	NULL
and	NULL
Carl	NULL
D.	NULL
Malchoff	NULL
*	NULL
*	NULL
Departments	NULL
of	NULL
Medicine	NULL
and	NULL
Surgery	NULL
,	NULL
University	NULL
of	NULL
Connecticut	NULL
Health	NULL
Center	NULL
,	NULL
Farmington	NULL
,	NULL
Connecticut	NULL
06030-1850	NULL
;	NULL
+81	NULL
.	NULL

Francis	NULL
Hospital	NULL
and	NULL
Medical	NULL
Center	NULL
,	NULL
Hartford	NULL
,	NULL
Connecticut	NULL
06105	NULL
;	NULL
and	NULL
§Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
University	NULL
of	NULL
Connecticut	NULL
Health	NULL
Center	NULL
,	NULL
Farmington	NULL
,	NULL
Connecticut	NULL
06030	NULL
Abstract	NULL
The	NULL
precise	NULL
molecular	NULL
abnormalities	NULL
that	NULL
cause	NULL
primary	NULL
cortisol	NULL
resistance	NULL
have	NULL
not	NULL
been	NULL
completely	NULL
described	NULL
.	NULL

In	NULL
a	NULL
subject	NULL
with	NULL
primary	NULL
cortisol	NULL
resistance	NULL
we	NULL
have	NULL
observed	NULL
glucocorticoid	NULL
receptors	NULL
(	NULL
hGR	NULL
)	NULL
with	NULL
a	NULL
decreased	NULL
affinity	NULL
for	NULL
dexamethasone	NULL
.	NULL

We	NULL
hypothesize	NULL
that	NULL
a	NULL
mutation	NULL
of	NULL
the	NULL
hGR	NULL
glucocorticoid-binding	NULL
domain	NULL
is	NULL
the	NULL
cause	NULL
of	NULL
cortisol	NULL
resistance	NULL
.	NULL

Total	NULL
RNA	NULL
isolated	NULL
from	NULL
the	NULL
index	NULL
subject	NULL
's	NULL
mononuclear	NULL
leukocytes	NULL
was	NULL
used	NULL
to	NULL
produce	NULL
first	NULL
strand	NULL
hGR	NULL
cDNAs	NULL
,	NULL
and	NULL
the	NULL
entire	NULL
hGR	NULL
cDNA	NULL
was	NULL
amplified	NULL
in	NULL
segments	NULL
and	NULL
sequenced	NULL
.	NULL

At	NULL
nucleotide	NULL
2,317	NULL
we	NULL
identified	NULL
a	NULL
homozygous	NULL
A	NULL
for	NULL
G	NULL
point	NULL
mutation	NULL
that	NULL
predicts	NULL
an	NULL
isoleucine	NULL
(	NULL
ATT	NULL
)	NULL
for	NULL
valine	NULL
(	NULL
GTT	NULL
)	NULL
substitution	NULL
at	NULL
amino	NULL
acid	NULL
729	NULL
.	NULL

When	NULL
the	NULL
wild-type	NULL
hGR	NULL
and	NULL
hGR-Ile	NULL
729	NULL
were	NULL
expressed	NULL
in	NULL
COS-1	NULL
cells	NULL
and	NULL
assayed	NULL
for	NULL
[	NULL
°H	NULL
]	NULL
-Dexamathasone	NULL
binding	NULL
,	NULL
the	NULL
dissociation	NULL
constants	NULL
were	NULL
0.799+0.068	NULL
and	NULL
1.54+0.06	NULL
nM	NULL
(	NULL
mean+SEM	NULL
)	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

When	NULL
the	NULL
wild-type	NULL
hGR	NULL
and	NULL
hGR-Ile	NULL
729	NULL
were	NULL
expressed	NULL
in	NULL
CV-1	NULL
cells	NULL
that	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
mouse	NULL
mammary	NULL
tumor	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
fused	NULL
to	NULL
the	NULL
chloramphenicol	NULL
acetyl	NULL
transferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
,	NULL
the	NULL
hGR-Ile	NULL
729	NULL
conferred	NULL
a	NULL
fourfold	NULL
decrease	NULL
in	NULL
apparent	NULL
potency	NULL
on	NULL
dexamethasone	NULL
stimulation	NULL
of	NULL
CAT	NULL
activity	NULL
.	NULL

The	NULL
isoleucine	NULL
for	NULL
valine	NULL
substitution	NULL
at	NULL
amino	NULL
acid	NULL
729	NULL
impairs	NULL
the	NULL
function	NULL
of	NULL
the	NULL
hGR	NULL
and	NULL
is	NULL
the	NULL
likely	NULL
cause	NULL
of	NULL
primary	NULL
cortisol	NULL
resistance	NULL
in	NULL
this	NULL
subject	NULL
.	NULL

(	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

1993	NULL
.	NULL

91:1918-1925	NULL
.	NULL
)	NULL

Key	NULL
words	NULL
:	NULL
primary	NULL
cortisol	NULL
resistance	NULL
«	NULL
glucocorticoid	NULL
receptor	NULL
mutation	NULL
*	NULL
isosexual	NULL
precocious	NULL
pseudopuberty	NULL
«	NULL
polymerase	NULL
chain	NULL
reaction	NULL
+	NULL
hypercortisolism	NULL
Introduction	NULL
Investigations	NULL
of	NULL
hormone	NULL
resistance	NULL
syndromes	NULL
have	NULL
classically	NULL
yielded	NULL
critical	NULL
information	NULL
concerning	NULL
the	NULL
mechanisms	NULL
of	NULL
hormone	NULL
action	NULL
.	NULL

Primary	NULL
cortisol	NULL
resistance	NULL
,	NULL
first	NULL
described	NULL
by	NULL
Vingerhoeds	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1	NULL
)	NULL
,	NULL
is	NULL
a	NULL
rare	NULL
inherited	NULL
disorder	NULL
characterized	NULL
by	NULL
hypercortisolism	NULL
without	NULL
Cushingoid	NULL
features	NULL
.	NULL

Clinical	NULL
manifestations	NULL
,	NULL
if	NULL
any	NULL
,	NULL
are	NULL
secondary	NULL
to	NULL
excess	NULL
circulating	NULL
This	NULL
work	NULL
was	NULL
presented	NULL
in	NULL
part	NULL
at	NULL
the	NULL
1990	NULL
National	NULL
Meeting	NULL
of	NULL
the	NULL
Association	NULL
of	NULL
American	NULL
Physicians	NULL
,	NULL
Washington	NULL
,	NULL
DC	NULL
,	NULL
and	NULL
the	NULL
1991	NULL
National	NULL
Meeting	NULL
of	NULL
the	NULL
Endocrine	NULL
Society	NULL
,	NULL
Washington	NULL
,	NULL
DC	NULL
.	NULL

Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
C.	NULL
Malchoff	NULL
,	NULL
Department	NULL
of	NULL
Surgery	NULL
,	NULL
University	NULL
of	NULL
Connecticut	NULL
Health	NULL
Center	NULL
,	NULL
263	NULL
Farmington	NULL
Ave.	NULL
,	NULL
Farmington	NULL
,	NULL
CT	NULL
06030-1110	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
15	NULL
April	NULL
1992	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
3	NULL
September	NULL
1992	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

©	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
0021-9738/93/05/1918/08	NULL
$	NULL
2.00	NULL
Volume	NULL
91	NULL
,	NULL
May	NULL
1993	NULL
,	NULL
1918-1925	NULL
nonglucocorticoid	NULL
adrenal	NULL
steroids	NULL
(	NULL
1-10	NULL
)	NULL
,	NULL
which	NULL
cause	NULL
hypertension	NULL
with	NULL
hypokalemia	NULL
(	NULL
2	NULL
)	NULL
and/or	NULL
signs	NULL
of	NULL
androgen	NULL
excess	NULL
(	NULL
7	NULL
,	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Abnormalities	NULL
of	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
hGR	NULL
)	NULL
'	NULL
number	NULL
(	NULL
4	NULL
,	NULL
8	NULL
,	NULL
10	NULL
)	NULL
,	NULL
affinity	NULL
for	NULL
DNA	NULL
(	NULL
5	NULL
)	NULL
,	NULL
affinity	NULL
for	NULL
glucocorticoids	NULL
(	NULL
2	NULL
,	NULL
9	NULL
,	NULL
10	NULL
)	NULL
,	NULL
and	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
6	NULL
)	NULL
have	NULL
been	NULL
described	NULL
.	NULL

The	NULL
molecular	NULL
basis	NULL
for	NULL
this	NULL
disorder	NULL
has	NULL
been	NULL
determined	NULL
for	NULL
one	NULL
subject	NULL
(	NULL
11	NULL
)	NULL
but	NULL
is	NULL
generally	NULL
un-known	NULL
.	NULL

We	NULL
recently	NULL
described	NULL
a	NULL
6-7/12-yr-old	NULL
boy	NULL
with	NULL
primary	NULL
cortisol	NULL
resistance	NULL
and	NULL
isosex	NULL
ual	NULL
precocious	NULL
pseudopuberty	NULL
resulting	NULL
from	NULL
excess	NULL
adrenal	NULL
androgen	NULL
secretion	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Dexamethasone	NULL
binding	NULL
to	NULL
hGR	NULL
of	NULL
intact	NULL
fresh	NULL
mononuclear	NULL
leukocytes	NULL
(	NULL
MNL	NULL
)	NULL
revealed	NULL
a	NULL
K	NULL
,	NULL
two-	NULL
to	NULL
threefold	NULL
greater	NULL
than	NULL
controls	NULL
and	NULL
normal	NULL
binding	NULL
capacity	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
hGR	NULL
is	NULL
compartmenta-lized	NULL
.	NULL

The	NULL
two	NULL
major	NULL
functional	NULL
domains	NULL
are	NULL
the	NULL
DNA-binding	NULL
domain	NULL
,	NULL
which	NULL
is	NULL
in	NULL
the	NULL
mid-region	NULL
of	NULL
the	NULL
molecule	NULL
,	NULL
and	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
,	NULL
which	NULL
is	NULL
at	NULL
the	NULL
carboxyl	NULL
terminus	NULL
(	NULL
12-16	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
ligand-binding	NULL
affinity	NULL
in	NULL
this	NULL
subject	NULL
is	NULL
decreased	NULL
,	NULL
we	NULL
hypothesize	NULL
that	NULL
primary	NULL
cortisol	NULL
resistance	NULL
results	NULL
from	NULL
a	NULL
mutation	NULL
of	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
of	NULL
the	NULL
hGR	NULL
.	NULL

We	NULL
now	NULL
describe	NULL
a	NULL
point	NULL
mutation	NULL
of	NULL
the	NULL
hGR	NULL
mRNA	NULL
that	NULL
predicts	NULL
a	NULL
change	NULL
in	NULL
the	NULL
primary	NULL
structure	NULL
of	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
and	NULL
alters	NULL
hGR	NULL
function	NULL
.	NULL

Methods	NULL
Subjects	NULL
.	NULL

The	NULL
index	NULL
subject	NULL
was	NULL
a	NULL
6-7/12-yr-old	NULL
Hispanic	NULL
boy	NULL
with	NULL
isosexual	NULL
precocious	NULL
pseudopuberty	NULL
.	NULL

The	NULL
clinical	NULL
and	NULL
biochemical	NULL
evidence	NULL
for	NULL
primary	NULL
cortisol	NULL
resistance	NULL
has	NULL
been	NULL
described	NULL
elsewhere	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
mother	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
is	NULL
a	NULL
26-yr-old	NULL
Hispanic	NULL
woman	NULL
with	NULL
no	NULL
known	NULL
medical	NULL
problems	NULL
including	NULL
hirsutism	NULL
,	NULL
hypertension	NULL
,	NULL
or	NULL
infertil-ity	NULL
.	NULL

The	NULL
father	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
was	NULL
unavailable	NULL
for	NULL
analysis	NULL
but	NULL
is	NULL
a	NULL
first	NULL
cousin	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
's	NULL
mother	NULL
.	NULL

One	NULL
source	NULL
of	NULL
control	NULL
RNA	NULL
was	NULL
fresh	NULL
MNL	NULL
from	NULL
a	NULL
healthy	NULL
unaffected	NULL
adult	NULL
.	NULL

The	NULL
other	NULL
source	NULL
of	NULL
control	NULL
RNA	NULL
was	NULL
early	NULL
passage	NULL
explant	NULL
skin	NULL
fibroblasts	NULL
from	NULL
an	NULL
unaffected	NULL
10-yr-old	NULL
child	NULL
,	NULL
which	NULL
were	NULL
maintained	NULL
in	NULL
continuous	NULL
culture	NULL
in	NULL
DME	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
FCS	NULL
.	NULL

The	NULL
study	NULL
was	NULL
approved	NULL
by	NULL
the	NULL
Institutional	NULL
Review	NULL
Board	NULL
at	NULL
the	NULL
University	NULL
of	NULL
Connecticut	NULL
Health	NULL
Center	NULL
.	NULL

Binding	NULL
of	NULL
[	NULL
6.7-°H	NULL
]	NULL
dexamethasone	NULL
(	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
)	NULL
to	NULL
glucocorticoid	NULL
receptors	NULL
of	NULL
intact	NULL
MNL	NULL
.	NULL

MNL	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
his	NULL
mother	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
(	NULL
50	NULL
Ci/mmol	NULL
;	NULL
New	NULL
England	NULL
Nuclear	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
to	NULL
the	NULL
hGR	NULL
of	NULL
intact	NULL
MNL	NULL
and	NULL
analysis	NULL
of	NULL
results	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
9	NULL
)	NULL
.	NULL

RNA	NULL
extraction	NULL
and	NULL
cDNA	NULL
production	NULL
.	NULL

Table	NULL
I	NULL
summarizes	NULL
the	NULL
relevant	NULL
characteristics	NULL
of	NULL
the	NULL
hGR	NULL
structure	NULL
and	NULL
the	NULL
primers	NULL
used	NULL
to	NULL
investigate	NULL
the	NULL
hGR	NULL
cDNA	NULL
sequence	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
extracted	NULL
from	NULL
MNL	NULL
or	NULL
fibroblasts	NULL
by	NULL
the	NULL
acid-guanidinium-phenol-chloroform	NULL
method	NULL
of	NULL
1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyl	NULL
transferase	NULL
;	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
,	NULL
[	NULL
6,7-*H	NULL
]	NULL
dexamethasone	NULL
;	NULL
hGR	NULL
,	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
;	NULL
MNL	NULL
,	NULL
mononuclear	NULL
leukocytes	NULL
.	NULL

1918	NULL
_-	NULL
Malchoff	NULL
,	NULL
Brufsky	NULL
,	NULL
Reardon	NULL
,	NULL
McDermott	NULL
,	NULL
Javier	NULL
,	NULL
Bergh	NULL
,	NULL
Rowe	NULL
,	NULL
and	NULL
Malchoff	NULL
Table	NULL
I	NULL
.	NULL

Summary	NULL
of	NULL
hGR	NULL
Structure	NULL
and	NULL
Amplification	NULL
Primers	NULL
with	NULL
Corresponding	NULL
Nucleotides	NULL
and	NULL
Amino	NULL
Acids	NULL
Nucleotide	NULL
Amino	NULL
acid	NULL
Significance	NULL
1-4,800	NULL
1-777	NULL
Entire	NULL
hGR	NULL
cDNA	NULL
1-132	NULL
None	NULL
5	NULL
'	NULL
untranslated	NULL
region	NULL
133-2,463	NULL
1-777	NULL
Entire	NULL
hGR	NULL
coding	NULL
region	NULL
2,464-4,800	NULL
None	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
1,365-1,599	NULL
411-489	NULL
DNA-binding	NULL
domain	NULL
1,714-2,463	NULL
528-777	NULL
Glucocorticoid-binding	NULL
domain	NULL
as	NULL
2,599-2,634	NULL
_	NULL
3	NULL
untranslated	NULL
_	NULL
Reverse	NULL
transcriptase	NULL
primer	NULL
region	NULL
as	NULL
1,260-1,294	NULL
_	NULL
376-387	NULL
Reverse	NULL
transcriptase	NULL
primer	NULL
34-59	NULL
5	NULL
'	NULL
untranslated	NULL
_	NULL
GluR5	NULL
,	NULL
PCR	NULL
primer	NULL
region	NULL
57-75	NULL
(	NULL
A	NULL
at	NULL
69	NULL
)	NULL
_	NULL
5	NULL
'	NULL
untranslated	NULL
_	NULL
GluR	NULL
14	NULL
,	NULL
PCR	NULL
primer	NULL
,	NULL
creating	NULL
region	NULL
a	NULL
new	NULL
Taq	NULL
!	NULL

restriction	NULL
site	NULL
449-473	NULL
106-113	NULL
GluR7	NULL
,	NULL
PCR	NULL
primer	NULL
as	NULL
538-562	NULL
135-143	NULL
GluR6	NULL
,	NULL
PCR	NULL
primer	NULL
1,151-1,175	NULL
339-348	NULL
GluR11	NULL
,	NULL
PCR	NULL
primer	NULL
as	NULL
1,248-1,276	NULL
_	NULL
372-381	NULL
GluR	NULL
13	NULL
,	NULL
PCR	NULL
primer	NULL
1,574-1,598	NULL
480-488	NULL
GluR4	NULL
,	NULL
PCR	NULL
primer	NULL
as	NULL
1,633-1,657	NULL
_	NULL
501-509	NULL
GluR9	NULL
,	NULL
PCR	NULL
primer	NULL
as	NULL
2,526-2,550	NULL
_	NULL
3	NULL
untranslated	NULL
_	NULL
GluR3	NULL
,	NULL
PCR	NULL
primer	NULL
region	NULL
2,236-2,260	NULL
701-709	NULL
GluR	NULL
10	NULL
,	NULL
PCR	NULL
primer	NULL
as	NULL
2,361-2,379	NULL
PCRS4	NULL
,	NULL
sequencing	NULL
primer	NULL
Chomezynski	NULL
and	NULL
Saachi	NULL
(	NULL
17	NULL
)	NULL
and	NULL
precipitated	NULL
twice	NULL
with	NULL
ethanol	NULL
before	NULL
use	NULL
.	NULL

First-strand	NULL
cDNAs	NULL
were	NULL
synthesized	NULL
from	NULL
this	NULL
RNA	NULL
by	NULL
standard	NULL
methods	NULL
(	NULL
18	NULL
)	NULL
.	NULL

To	NULL
prepare	NULL
hGR	NULL
cDNAs	NULL
for	NULL
the	NULL
carboxyl	NULL
half	NULL
of	NULL
the	NULL
molecule	NULL
,	NULL
we	NULL
used	NULL
a	NULL
35-mer	NULL
oligonucleotide	NULL
primer	NULL
complementary	NULL
to	NULL
nucleotides	NULL
2,599-2,634	NULL
,	NULL
which	NULL
are	NULL
in	NULL
the	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
the	NULL
alpha	NULL
form	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
(	NULL
19	NULL
)	NULL
,	NULL
to	NULL
prime	NULL
specific	NULL
first-strand	NULL
cDNA	NULL
synthesis	NULL
(	NULL
Table	NULL
I	NULL
and	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

A	NULL
35-mer	NULL
oligonucleotide	NULL
complementary	NULL
to	NULL
nucleotides	NULL
1,260-1,294	NULL
was	NULL
used	NULL
to	NULL
prime	NULL
specific	NULL
first-strand	NULL
cDNA	NULL
synthesis	NULL
upstream	NULL
of	NULL
the	NULL
middle	NULL
of	NULL
the	NULL
molecule	NULL
(	NULL
Table	NULL
I	NULL
and	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
5	NULL
ug	NULL
of	NULL
total	NULL
RNA	NULL
was	NULL
incubated	NULL
for	NULL
60	NULL
min	NULL
at	NULL
37°C	NULL
with	NULL
2.5	NULL
ug	NULL
35-mer	NULL
oligonucleotide	NULL
in	NULL
50	NULL
Ll	NULL
of	NULL
buffer	NULL
containing	NULL
50	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.3	NULL
)	NULL
,	NULL
75	NULL
mM	NULL
KCI	NULL
,	NULL
3	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
DTT	NULL
,	NULL
500	NULL
uM	NULL
dNTPs	NULL
,	NULL
and	NULL
250	NULL
U	NULL
MMuLV	NULL
reverse	NULL
transcriptase	NULL
(	NULL
Bethesda	NULL
Research	NULL
Laboratories	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
amplification	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
.	NULL

The	NULL
primers	NULL
and	NULL
strategy	NULL
for	NULL
the	NULL
PCR	NULL
amplification	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
and	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
coding	NULL
region	NULL
of	NULL
the	NULL
carboxyl	NULL
half	NULL
of	NULL
the	NULL
molecule	NULL
(	NULL
including	NULL
the	NULL
DNA-binding	NULL
and	NULL
glucocorticoid-binding	NULL
domains	NULL
)	NULL
was	NULL
amplified	NULL
with	NULL
the	NULL
template	NULL
being	NULL
the	NULL
cDNA	NULL
that	NULL
had	NULL
been	NULL
prepared	NULL
using	NULL
the	NULL
primer	NULL
complementary	NULL
to	NULL
nucleotides	NULL
2,599-2,634	NULL
.	NULL

To	NULL
PCR	NULL
amplify	NULL
the	NULL
region	NULL
coding	NULL
for	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
,	NULL
one	NULL
tenth	NULL
of	NULL
the	NULL
appropriate	NULL
cDNA	NULL
synthesis	NULL
reaction	NULL
(	NULL
5	NULL
ul	NULL
)	NULL
was	NULL
mixed	NULL
with	NULL
12.5	NULL
pmol	NULL
each	NULL
of	NULL
25-mer	NULL
oligonucleotides	NULL
GluR4	NULL
and	NULL
GluR3	NULL
'	NULL
(	NULL
Table	NULL
I	NULL
and	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
which	NULL
flanked	NULL
a	NULL
976-bp	NULL
region	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
coding	NULL
for	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
4	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
brought	NULL
to	NULL
100	NULL
ul	NULL
,	NULL
with	NULL
the	NULL
final	NULL
buffer	NULL
containing	NULL
50	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.3	NULL
)	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.01	NULL
%	NULL
gelatin	NULL
,	NULL
200	NULL
aM	NULL
dNTPs	NULL
,	NULL
and	NULL
2.5	NULL
U	NULL
Taq	NULL
polymerase	NULL
(	NULL
20	NULL
)	NULL
.	NULL

30	NULL
cycles	NULL
of	NULL
heating	NULL
to	NULL
94°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
cooling	NULL
to	NULL
50°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
and	NULL
heating	NULL
to	NULL
72°C	NULL
for	NULL
3.5	NULL
min	NULL
were	NULL
performed	NULL
on	NULL
a	NULL
thermal	NULL
cycler	NULL
(	NULL
model	NULL
2600	NULL
;	NULL
Perkin-Elmer	NULL
Cetus	NULL
In-struments	NULL
,	NULL
Norwalk	NULL
,	NULL
CT	NULL
)	NULL
with	NULL
a	NULL
7-min	NULL
incubation	NULL
at	NULL
72°C	NULL
after	NULL
the	NULL
30th	NULL
cycle	NULL
.	NULL

The	NULL
successful	NULL
amplification	NULL
of	NULL
a	NULL
specific	NULL
976-bp	NULL
fragment	NULL
was	NULL
determined	NULL
by	NULL
electrophoresis	NULL
of	NULL
a	NULL
10-4l	NULL
aliquot	NULL
of	NULL
the	NULL
reaction	NULL
on	NULL
a	NULL
5	NULL
%	NULL
TBE-polyacrylamide	NULL
gel	NULL
(	NULL
21	NULL
)	NULL
and	NULL
staining	NULL
with	NULL
ethidium	NULL
bromide	NULL
.	NULL

Alternatively	NULL
,	NULL
a	NULL
31	NULL
1-bp	NULL
fragment	NULL
of	NULL
hGR	NULL
cDNA	NULL
was	NULL
PCR	NULL
ampli-	NULL
fied	NULL
from	NULL
10	NULL
Ll	NULL
of	NULL
first-strand	NULL
hGR	NULL
cDNA	NULL
by	NULL
the	NULL
above	NULL
methods	NULL
using	NULL
oligonucleotides	NULL
GluR	NULL
10	NULL
and	NULL
GluR3	NULL
(	NULL
Table	NULL
I	NULL
and	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

To	NULL
amplify	NULL
the	NULL
region	NULL
that	NULL
codes	NULL
for	NULL
the	NULL
hGR	NULL
DNA-binding	NULL
domain	NULL
,	NULL
a	NULL
506-bp	NULL
fragment	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
was	NULL
PCR	NULL
amplified	NULL
from	NULL
10	NULL
ul	NULL
of	NULL
the	NULL
appropriate	NULL
first-strand	NULL
hGR	NULL
cDNA	NULL
by	NULL
the	NULL
above	NULL
methods	NULL
using	NULL
oligonucleotides	NULL
GluR9	NULL
and	NULL
GluR	NULL
1	NULL
1	NULL
(	NULL
Table	NULL
I	NULL
and	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

To	NULL
amplify	NULL
the	NULL
remainder	NULL
of	NULL
the	NULL
molecule	NULL
,	NULL
the	NULL
cDNA	NULL
prepared	NULL
with	NULL
the	NULL
primer	NULL
complementary	NULL
to	NULL
nucleotides	NULL
1,260-1,294	NULL
was	NULL
used	NULL
as	NULL
the	NULL
template	NULL
.	NULL

Using	NULL
GluR7	NULL
,	NULL
GluR13	NULL
,	NULL
and	NULL
the	NULL
PCR	NULL
reagents	NULL
described	NULL
above	NULL
,	NULL
an	NULL
827-bp	NULL
DNA	NULL
fragment	NULL
was	NULL
amplified	NULL
with	NULL
the	NULL
following	NULL
conditions	NULL
:	NULL
30	NULL
cycles	NULL
of	NULL
heating	NULL
to	NULL
94°C	NULL
for	NULL
l	NULL
min	NULL
,	NULL
cooling	NULL
to	NULL
50°C	NULL
for	NULL
I	NULL
min	NULL
,	NULL
and	NULL
heating	NULL
to	NULL
72°C	NULL
for	NULL
3.5	NULL
min	NULL
.	NULL

Using	NULL
GluR5	NULL
,	NULL
GluR6	NULL
,	NULL
and	NULL
the	NULL
PCR	NULL
reagents	NULL
and	NULL
conditions	NULL
described	NULL
above	NULL
,	NULL
a	NULL
528-bp	NULL
DNA	NULL
fragment	NULL
that	NULL
included	NULL
the	NULL
5	NULL
'	NULL
untranslated	NULL
region	NULL
was	NULL
amplified	NULL
.	NULL

3	NULL
xl	NULL
of	NULL
this	NULL
reaction	NULL
was	NULL
reamplified	NULL
using	NULL
primers	NULL
GluR14	NULL
and	NULL
GluR6	NULL
and	NULL
the	NULL
same	NULL
reaction	NULL
conditions	NULL
to	NULL
produce	NULL
a	NULL
502-bp	NULL
fragment	NULL
.	NULL

GluR	NULL
14	NULL
introduces	NULL
a	NULL
new	NULL
Tag	NULL
]	NULL
restriction	NULL
enzyme	NULL
site	NULL
at	NULL
position	NULL
67	NULL
by	NULL
substituting	NULL
an	NULL
A	NULL
for	NULL
G	NULL
at	NULL
position	NULL
69	NULL
.	NULL

This	NULL
site	NULL
is	NULL
used	NULL
for	NULL
subcloning	NULL
.	NULL

DNA	NULL
sequencing	NULL
.	NULL

The	NULL
amplified	NULL
976-bp	NULL
fragment	NULL
carrying	NULL
the	NULL
coding	NULL
region	NULL
for	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
was	NULL
isolated	NULL
from	NULL
the	NULL
PCR	NULL
mixture	NULL
by	NULL
electroelution	NULL
(	NULL
21	NULL
)	NULL
,	NULL
cleaved	NULL
with	NULL
Taq	NULL
!	NULL

(	NULL
nucleotides	NULL
1,602	NULL
and	NULL
2,500	NULL
)	NULL
,	NULL
and	NULL
ligated	NULL
into	NULL
the	NULL
Ace	NULL
!	NULL

site	NULL
of	NULL
pBS	NULL
SK+	NULL
(	NULL
Strata-gene	NULL
,	NULL
Inc.	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
amplified	NULL
31	NULL
-bp	NULL
fragment	NULL
was	NULL
isolated	NULL
by	NULL
electroelution	NULL
,	NULL
cleaved	NULL
with	NULL
Nsil	NULL
(	NULL
nucleotide	NULL
2,309	NULL
)	NULL
and	NULL
Tagl	NULL
(	NULL
nucleotide	NULL
2,500	NULL
)	NULL
,	NULL
and	NULL
ligated	NULL
into	NULL
the	NULL
PstI	NULL
and	NULL
Accel	NULL
sites	NULL
of	NULL
pBS	NULL
SK+	NULL
.	NULL

The	NULL
506-bp	NULL
fragment	NULL
carrying	NULL
the	NULL
region	NULL
coding	NULL
for	NULL
the	NULL
DNA-binding	NULL
domain	NULL
was	NULL
cleaved	NULL
with	NULL
Styl	NULL
(	NULL
nucleotide	NULL
1,233	NULL
)	NULL
and	NULL
EcoRI	NULL
(	NULL
nucleotide	NULL
1,628	NULL
)	NULL
and	NULL
ligated	NULL
into	NULL
the	NULL
Xbal	NULL
and	NULL
EcoRI	NULL
sites	NULL
of	NULL
pBS	NULL
SK+	NULL
.	NULL

The	NULL
amplified	NULL
827-bp	NULL
fragment	NULL
was	NULL
cleaved	NULL
with	NULL
HindIII	NULL
(	NULL
nucleotides	NULL
490	NULL
and	NULL
1,044	NULL
)	NULL
and	NULL
the	NULL
resultant	NULL
fragment	NULL
ligated	NULL
into	NULL
pBS	NULL
SK+	NULL
cleaved	NULL
with	NULL
HindIII	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
also	NULL
cut	NULL
with	NULL
BstYI	NULL
(	NULL
nucleotides	NULL
915	NULL
and	NULL
1,237	NULL
)	NULL
and	NULL
ligated	NULL
into	NULL
pBS	NULL
SK+	NULL
cleaved	NULL
with	NULL
BamHI	NULL
.	NULL

The	NULL
502-bp	NULL
fragment	NULL
was	NULL
cleaved	NULL
with	NULL
Taql	NULL
(	NULL
nucleotides	NULL
67	NULL
and	NULL
526	NULL
)	NULL
and	NULL
ligated	NULL
into	NULL
pBS	NULL
SK+	NULL
cleaved	NULL
with	NULL
Accel	NULL
.	NULL

The	NULL
recombinant	NULL
plasmids	NULL
were	NULL
used	NULL
to	NULL
transform	NULL
Escherichia	NULL
coli	NULL
.	NULL

Recombinant	NULL
plasmid	NULL
DNAs	NULL
were	NULL
isolated	NULL
from	NULL
single-banded	NULL
CsCI	NULL
preparations	NULL
of	NULL
single	NULL
recombinant	NULL
bacterial	NULL
colonies	NULL
and	NULL
sequenced	NULL
by	NULL
the	NULL
dideoxy	NULL
method	NULL
(	NULL
22	NULL
)	NULL
,	NULL
using	NULL
[	NULL
S	NULL
]	NULL
dATP	NULL
and	NULL
the	NULL
universal	NULL
primer	NULL
,	NULL
T3	NULL
primer	NULL
,	NULL
and	NULL
internal	NULL
primers	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
the	NULL
31	NULL
1-bp	NULL
PCR	NULL
reactions	NULL
(	NULL
90	NULL
ul	NULL
)	NULL
were	NULL
precipitated	NULL
twice	NULL
with	NULL
ammonium	NULL
acetate	NULL
and	NULL
ethanol	NULL
and	NULL
sequenced	NULL
directly	NULL
using	NULL
~50	NULL
ng	NULL
(	NULL
2	NULL
x	NULL
10°	NULL
cpm	NULL
)	NULL
of	NULL
a	NULL
[	NULL
P	NULL
]	NULL
dCTP-labeled	NULL
internal	NULL
hGR-specific	NULL
oligonucleotide	NULL
(	NULL
PCRS4	NULL
,	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
as	NULL
a	NULL
sequencing	NULL
primer	NULL
(	NULL
22	NULL
)	NULL
.	NULL

All	NULL
sequencing	NULL
reactions	NULL
were	NULL
analyzed	NULL
on	NULL
denaturing	NULL
6	NULL
%	NULL
TBE-urea	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

At	NULL
least	NULL
10	NULL
recombinant	NULL
clones	NULL
were	NULL
se	NULL
4	NULL
3000	NULL
RT	NULL
o	NULL
<	NULL
>	NULL
...	NULL
...	NULL
...	NULL
...	NULL
...	NULL
...	NULL
...	NULL
...	NULL
ron	NULL
mall	NULL
-	NULL
PCR	NULL
with	NULL
--	NULL
--	NULL
--	NULL
-	NULL
<	NULL
Direct	NULL
Sequencing	NULL
~lfprmmmmmmmmmmmesmmum	NULL
RT	NULL
#	NULL
m	NULL
.~	NULL
(	NULL
Bcc	NULL
ccc	NULL
cll	NULL
}	NULL
«	NULL
tlp	NULL
pon	NULL
Figure	NULL
1	NULL
.	NULL

Strategy	NULL
for	NULL
PCR	NULL
amplification	NULL
and	NULL
sequencing	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
.	NULL

The	NULL
first	NULL
3,000	NULL
nucleotides	NULL
of	NULL
the	NULL
hGR	NULL
mRNA	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
top	NULL
thick	NULL
black	NULL
line	NULL
.	NULL

The	NULL
strategy	NULL
for	NULL
reverse	NULL
transcription	NULL
(	NULL
RT	NULL
)	NULL
and	NULL
PCR	NULL
amplification	NULL
of	NULL
cDNA	NULL
are	NULL
indicated	NULL
.	NULL

These	NULL
fragments	NULL
were	NULL
subcloned	NULL
and	NULL
sequenced	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
.	NULL

The	NULL
region	NULL
containing	NULL
the	NULL
mutation	NULL
at	NULL
cDNA	NULL
nucleotide	NULL
2,317	NULL
was	NULL
also	NULL
sequenced	NULL
by	NULL
direct	NULL
sequencing	NULL
of	NULL
PCR	NULL
products	NULL
as	NULL
indicated	NULL
.	NULL

Glucocorticoid	NULL
Receptor	NULL
Mutation	NULL
__	NULL
1919	NULL
Genomic	NULL
DNA	NULL
Sequence	NULL
Wild	NULL
Intron	NULL
H	NULL
...	NULL
tcattaccatatcttctcttgcag	NULL
GTGGTT..Exon	NULL
90	NULL
.	NULL

Mutant	NULL
-	NULL
Intron	NULL
H	NULL
...	NULL
tcattaccatatcttctettgcag	NULL
GTGATT	NULL
...	NULL
Exon	NULL
90	NULL
.	NULL

(	NULL
A	NULL
at	NULL
2317	NULL
)	NULL
-=	NULL
PCR	NULL
Primer	NULL
RE2	NULL
PCR	NULL
AMPLIFIED	NULL
DNA	NULL
Bsi	NULL
|	NULL
Wild	NULL
Type	NULL
5	NULL
'	NULL
.	NULL

``	NULL
CTCCTGCAGYETGG'ITGAAAATCT	NULL
...	NULL
.3	NULL
'	NULL
Mutant	NULL
5	NULL
'	NULL
...	NULL
CTCCTGCAGGTGATTGAAAATCT	NULL
...	NULL
.3	NULL
'	NULL
(	NULL
A	NULL
at	NULL
2317	NULL
)	NULL
Hph	NULL
I	NULL
Figure	NULL
2	NULL
.	NULL

Strategy	NULL
for	NULL
detecting	NULL
the	NULL
A	NULL
for	NULL
G	NULL
substitution	NULL
at	NULL
nucleotide	NULL
2,317	NULL
in	NULL
genomic	NULL
DNA	NULL
.	NULL

The	NULL
A	NULL
for	NULL
G	NULL
substitution	NULL
at	NULL
hGR	NULL
cDNA	NULL
nucleotide	NULL
2317	NULL
(	NULL
underlined	NULL
)	NULL
is	NULL
near	NULL
the	NULL
border	NULL
of	NULL
the	NULL
ninth	NULL
exon	NULL
and	NULL
the	NULL
H	NULL
intron	NULL
and	NULL
creates	NULL
a	NULL
new	NULL
HphI	NULL
site	NULL
in	NULL
the	NULL
genomic	NULL
DNA	NULL
.	NULL

The	NULL
appropriate	NULL
regions	NULL
of	NULL
both	NULL
the	NULL
wild-type	NULL
and	NULL
the	NULL
mutant	NULL
sequences	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
upstream	NULL
primer	NULL
(	NULL
RE2	NULL
)	NULL
used	NULL
for	NULL
PCR	NULL
amplifying	NULL
this	NULL
region	NULL
of	NULL
the	NULL
genomic	NULL
DNA	NULL
is	NULL
identical	NULL
to	NULL
the	NULL
wild-type	NULL
sequence	NULL
except	NULL
for	NULL
a	NULL
C	NULL
that	NULL
is	NULL
substituted	NULL
for	NULL
a	NULL
T	NULL
at	NULL
the	NULL
position	NULL
indicated	NULL
by	NULL
a	NULL
box	NULL
.	NULL

This	NULL
substitution	NULL
creates	NULL
a	NULL
new	NULL
restriction	NULL
site	NULL
in	NULL
the	NULL
resultant	NULL
fragment	NULL
when	NULL
the	NULL
wild-type	NULL
genomic	NULL
DNA	NULL
is	NULL
amplified	NULL
but	NULL
not	NULL
when	NULL
the	NULL
mutant	NULL
genomic	NULL
DNA	NULL
is	NULL
amplified	NULL
.	NULL

The	NULL
resultant	NULL
fragment	NULL
from	NULL
PCR	NULL
amplification	NULL
of	NULL
the	NULL
wild-type	NULL
genomic	NULL
DNA	NULL
contains	NULL
the	NULL
BslI	NULL
(	NULL
CCNNNNN/NNGG	NULL
)	NULL
restriction	NULL
site	NULL
,	NULL
but	NULL
not	NULL
the	NULL
HphI	NULL
site	NULL
.	NULL

The	NULL
resultant	NULL
fragment	NULL
from	NULL
PCR	NULL
amplification	NULL
of	NULL
the	NULL
mutant	NULL
genomic	NULL
DNA	NULL
contains	NULL
the	NULL
Hphl	NULL
(	NULL
GGTGANNNNNNNN/	NULL
)	NULL
restriction	NULL
site	NULL
,	NULL
but	NULL
not	NULL
the	NULL
BslI	NULL
site	NULL
.	NULL

The	NULL
uncut	NULL
PCR	NULL
amplified	NULL
fragment	NULL
is	NULL
96	NULL
bp	NULL
when	NULL
either	NULL
the	NULL
wild-type	NULL
or	NULL
mutant	NULL
genomic	NULL
DNA	NULL
is	NULL
used	NULL
as	NULL
the	NULL
template	NULL
.	NULL

Cleavage	NULL
of	NULL
the	NULL
fragment	NULL
amplified	NULL
from	NULL
the	NULL
wild-type	NULL
genomic	NULL
DNA	NULL
with	NULL
BslI	NULL
yields	NULL
a	NULL
72-bp	NULL
fragment	NULL
,	NULL
and	NULL
cleavage	NULL
of	NULL
the	NULL
fragment	NULL
amplified	NULL
from	NULL
the	NULL
mutant	NULL
genomic	NULL
DNA	NULL
with	NULL
Hphl	NULL
yields	NULL
a	NULL
60-bp	NULL
fragment	NULL
.	NULL

quenced	NULL
for	NULL
the	NULL
patient	NULL
,	NULL
his	NULL
mother	NULL
,	NULL
and	NULL
the	NULL
two	NULL
controls	NULL
,	NULL
and	NULL
at	NULL
least	NULL
two	NULL
independent	NULL
PCR	NULL
reactions	NULL
were	NULL
sequenced	NULL
from	NULL
each	NULL
of	NULL
the	NULL
four	NULL
subjects	NULL
directly	NULL
.	NULL

Sequence	NULL
was	NULL
compared	NULL
with	NULL
the	NULL
published	NULL
sequence	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
genomic	NULL
DNA	NULL
.	NULL

The	NULL
genomic	NULL
DNA	NULL
was	NULL
isolated	NULL
from	NULL
MNL	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
,	NULL
his	NULL
mother	NULL
,	NULL
and	NULL
20	NULL
unaffected	NULL
normal	NULL
controls	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Gross-Bellard	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
.	NULL

This	NULL
DNA	NULL
was	NULL
used	NULL
as	NULL
a	NULL
template	NULL
for	NULL
PCR	NULL
amplification	NULL
of	NULL
the	NULL
region	NULL
of	NULL
the	NULL
genomic	NULL
DNA	NULL
carrying	NULL
the	NULL
A	NULL
for	NULL
G	NULL
substitution	NULL
at	NULL
cDNA	NULL
nucleotide	NULL
position	NULL
2,317	NULL
.	NULL

Fig	NULL
.	NULL

2	NULL
shows	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
intron-exon	NULL
junction	NULL
(	NULL
24	NULL
)	NULL
,	NULL
the	NULL
selection	NULL
of	NULL
the	NULL
PCR	NULL
primers	NULL
,	NULL
and	NULL
the	NULL
strategy	NULL
for	NULL
analyzing	NULL
the	NULL
genomic	NULL
DNA	NULL
for	NULL
the	NULL
hGR	NULL
cDNA	NULL
mutation	NULL
at	NULL
position	NULL
2,317	NULL
.	NULL

This	NULL
mutation	NULL
introduces	NULL
a	NULL
new	NULL
Hph	NULL
]	NULL
I	NULL
cleavage	NULL
site	NULL
not	NULL
present	NULL
in	NULL
the	NULL
wild-type	NULL
DNA	NULL
.	NULL

Primer	NULL
RE2	NULL
carries	NULL
single-base	NULL
mismatch	NULL
to	NULL
create	NULL
a	NULL
Bsl	NULL
I	NULL
restriction	NULL
site	NULL
in	NULL
the	NULL
wild-type	NULL
genome	NULL
but	NULL
not	NULL
in	NULL
the	NULL
genome	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

50	NULL
ng	NULL
of	NULL
genomic	NULL
DNA	NULL
was	NULL
mixed	NULL
with	NULL
12.5	NULL
pmol	NULL
each	NULL
of	NULL
the	NULL
primers	NULL
(	NULL
Table	NULL
I	NULL
and	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
brought	NULL
to	NULL
100	NULL
gl	NULL
with	NULL
the	NULL
final	NULL
buffer	NULL
containing	NULL
50	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.3	NULL
)	NULL
,	NULL
1.5	NULL
mM	NULL
MgC	NULL
)	NULL
;	NULL
,	NULL
0.01	NULL
%	NULL
gelatin	NULL
,	NULL
200	NULL
uM	NULL
dNTPs	NULL
,	NULL
and	NULL
2.5	NULL
U	NULL
Taq	NULL
polymerase	NULL
(	NULL
20	NULL
)	NULL
.	NULL

30	NULL
cycles	NULL
of	NULL
heating	NULL
to	NULL
94°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
cooling	NULL
to	NULL
51°C	NULL
for	NULL
0.75	NULL
min	NULL
,	NULL
and	NULL
heating	NULL
to	NULL
72°C	NULL
for	NULL
1.5	NULL
min	NULL
with	NULL
a	NULL
4-min	NULL
incubation	NULL
at	NULL
72°C	NULL
after	NULL
the	NULL
30th	NULL
cycle	NULL
were	NULL
used	NULL
to	NULL
amplify	NULL
a	NULL
96-bp	NULL
fragment	NULL
carrying	NULL
the	NULL
region	NULL
of	NULL
interest	NULL
.	NULL

This	NULL
PCR	NULL
product	NULL
was	NULL
precipitated	NULL
with	NULL
7.5	NULL
M	NULL
ammonium	NULL
acetate	NULL
and	NULL
100	NULL
%	NULL
ethanol	NULL
and	NULL
divided	NULL
into	NULL
three	NULL
equal	NULL
aliquots	NULL
;	NULL
one	NULL
was	NULL
left	NULL
uncut	NULL
,	NULL
one	NULL
was	NULL
cut	NULL
overnight	NULL
with	NULL
5	NULL
U	NULL
BslI	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
and	NULL
one	NULL
was	NULL
cut	NULL
overnight	NULL
with	NULL
4	NULL
U	NULL
of	NULL
HphI	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
}	NULL
.	NULL

Reaction	NULL
conditions	NULL
were	NULL
according	NULL
to	NULL
the	NULL
specifications	NULL
of	NULL
1920	NULL
the	NULL
manufacturer	NULL
.	NULL

The	NULL
products	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
6	NULL
%	NULL
TBE-polyacrylamide	NULL
minigel	NULL
and	NULL
stained	NULL
with	NULL
ethidium	NULL
bromide	NULL
.	NULL

Preparation	NULL
of	NULL
expression	NULL
vectors	NULL
.	NULL

An	NULL
expression	NULL
vector	NULL
carrying	NULL
the	NULL
identified	NULL
mutation	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
was	NULL
prepared	NULL
from	NULL
the	NULL
an	NULL
expression	NULL
vector	NULL
linking	NULL
the	NULL
RSV	NULL
LTR	NULL
to	NULL
full	NULL
length	NULL
wild-type	NULL
hGR	NULL
cDNA	NULL
(	NULL
pRShGRa	NULL
)	NULL
,	NULL
which	NULL
was	NULL
graciously	NULL
provided	NULL
by	NULL
Dr.	NULL
Stanley	NULL
M.	NULL
Hollenberg	NULL
(	NULL
The	NULL
Salk	NULL
Institute	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
;	NULL
reference	NULL
15	NULL
)	NULL
.	NULL

The	NULL
976-bp	NULL
PCR-amplified	NULL
cDNA	NULL
coding	NULL
for	NULL
the	NULL
entire	NULL
glucocorticoid-binding	NULL
domain	NULL
was	NULL
cleaved	NULL
with	NULL
Nsi1	NULL
(	NULL
nucleotide	NULL
2,309	NULL
)	NULL
and	NULL
Aval	NULL
(	NULL
2,380	NULL
)	NULL
to	NULL
generate	NULL
a	NULL
72-bp	NULL
fragment	NULL
containing	NULL
the	NULL
A	NULL
for	NULL
G	NULL
substitution	NULL
at	NULL
nucleotide	NULL
2,317	NULL
.	NULL

This	NULL
was	NULL
ligated	NULL
into	NULL
the	NULL
corresponding	NULL
Nsil	NULL
and	NULL
Aval	NULL
sites	NULL
of	NULL
the	NULL
BstXI-Xhol	NULL
fragment	NULL
of	NULL
the	NULL
pRShGRa	NULL
,	NULL
which	NULL
had	NULL
been	NULL
subcloned	NULL
into	NULL
pBS	NULL
SK+	NULL
.	NULL

The	NULL
Clal-Xhol	NULL
fragment	NULL
of	NULL
this	NULL
construct	NULL
was	NULL
ligated	NULL
into	NULL
the	NULL
corresponding	NULL
Clal	NULL
and	NULL
Xhol	NULL
sites	NULL
of	NULL
the	NULL
pRShGRa	NULL
to	NULL
create	NULL
an	NULL
expression	NULL
vector	NULL
for	NULL
the	NULL
mutant	NULL
hGR-Ile	NULL
729	NULL
.	NULL

This	NULL
vector	NULL
was	NULL
sequenced	NULL
in	NULL
its	NULL
entirety	NULL
to	NULL
be	NULL
sure	NULL
that	NULL
no	NULL
other	NULL
mutations	NULL
had	NULL
been	NULL
introduced	NULL
inadvertently	NULL
.	NULL

The	NULL
expression	NULL
vector	NULL
,	NULL
pMTVCAT	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
mouse	NULL
mammary	NULL
tumor	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
MTV	NULL
)	NULL
fused	NULL
to	NULL
the	NULL
cDNA	NULL
for	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
,	NULL
was	NULL
graciously	NULL
provided	NULL
by	NULL
Dr.	NULL
Stanley	NULL
Hollenberg	NULL
.	NULL

Transfection	NULL
of	NULL
mammalian	NULL
cells	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
ligand-binding	NULL
properties	NULL
of	NULL
wild-type	NULL
hGR	NULL
and	NULL
hGR-Ile	NULL
729	NULL
,	NULL
these	NULL
receptors	NULL
were	NULL
expressed	NULL
in	NULL
COS-1	NULL
cells	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
transfection	NULL
method	NULL
(	NULL
15	NULL
)	NULL
.	NULL

COS-1	NULL
cells	NULL
were	NULL
grown	NULL
at	NULL
37°C	NULL
in	NULL
DMEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
in	NULL
an	NULL
atmosphere	NULL
of	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
and	NULL
95	NULL
%	NULL
air	NULL
to	NULL
a	NULL
density	NULL
of	NULL
50	NULL
%	NULL
in	NULL
10-cm	NULL
culture	NULL
dishes	NULL
.	NULL

Media	NULL
was	NULL
aspirated	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
refed	NULL
with	NULL
4	NULL
ml	NULL
of	NULL
DMEM	NULL
containing	NULL
10	NULL
%	NULL
NuSerum	NULL
(	NULL
Collaborative	NULL
Research	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
vectors	NULL
,	NULL
which	NULL
had	NULL
been	NULL
purified	NULL
using	NULL
two	NULL
CsCI-EtBr	NULL
equilibrium	NULL
gradients	NULL
,	NULL
were	NULL
dissolved	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
0.25	NULL
ug/ul	NULL
,	NULL
and	NULL
40	NULL
«	NULL
l	NULL
of	NULL
this	NULL
solution	NULL
was	NULL
mixed	NULL
with	NULL
80	NULL
l	NULL
of	NULL
10	NULL
mg/ml	NULL
DEAE-dextran	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
and	NULL
added	NULL
dropwise	NULL
to	NULL
each	NULL
plate	NULL
of	NULL
COS-1	NULL
cells	NULL
.	NULL

After	NULL
a	NULL
4-h	NULL
incubation	NULL
at	NULL
37°C	NULL
,	NULL
the	NULL
medium	NULL
was	NULL
aspirated	NULL
from	NULL
the	NULL
plates	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
shocked	NULL
by	NULL
incubating	NULL
with	NULL
5	NULL
ml	NULL
of	NULL
10	NULL
%	NULL
DMSO	NULL
in	NULL
PBS	NULL
for	NULL
1	NULL
min	NULL
at	NULL
20°C	NULL
.	NULL

The	NULL
DMSO	NULL
solution	NULL
was	NULL
aspirated	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
5	NULL
ml	NULL
of	NULL
PBS	NULL
,	NULL
and	NULL
10	NULL
ml	NULL
of	NULL
complete	NULL
medium	NULL
was	NULL
added	NULL
to	NULL
each	NULL
plate	NULL
.	NULL

After	NULL
being	NULL
incubated	NULL
for	NULL
48	NULL
h	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
lysed	NULL
by	NULL
freezing	NULL
and	NULL
thawing	NULL
in	NULL
TEDGM	NULL
(	NULL
10	NULL
mM	NULL
Tris	NULL
,	NULL
1.5	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
3	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
10	NULL
mM	NULL
sodium	NULL
molybdate	NULL
)	NULL
,	NULL
centrifuged	NULL
at	NULL
100,000	NULL
g	NULL
for	NULL
60	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
,	NULL
which	NULL
had	NULL
a	NULL
final	NULL
protein	NULL
concentration	NULL
of	NULL
~2-5	NULL
mg/ml	NULL
,	NULL
was	NULL
assayed	NULL
for	NULL
dexamethasone	NULL
binding	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
wild-type	NULL
hGR	NULL
and	NULL
mutant	NULL
hGR-Ile	NULL
729	NULL
to	NULL
stimulate	NULL
gene	NULL
transcription	NULL
,	NULL
the	NULL
expression	NULL
vector	NULL
for	NULL
each	NULL
receptor	NULL
was	NULL
cotransfected	NULL
with	NULL
pMTVCAT	NULL
into	NULL
CV-1	NULL
cells	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
method	NULL
(	NULL
15	NULL
)	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
MEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
at	NULL
37°C	NULL
in	NULL
10-cm	NULL
plates	NULL
and	NULL
split	NULL
24	NULL
h	NULL
before	NULL
transfection	NULL
.	NULL

For	NULL
each	NULL
plate	NULL
10	NULL
ug	NULL
of	NULL
pMTVCAT	NULL
and	NULL
the	NULL
expression	NULL
vector	NULL
for	NULL
the	NULL
normal	NULL
or	NULL
mutant	NULL
hGR	NULL
were	NULL
dissolved	NULL
in	NULL
450	NULL
ul	NULL
sterile	NULL
water	NULL
and	NULL
combined	NULL
with	NULL
50	NULL
gl	NULL
2.5	NULL
M	NULL
CaCl	NULL
;	NULL
.	NULL

This	NULL
solution	NULL
was	NULL
then	NULL
added	NULL
to	NULL
500	NULL
Ll	NULL
of	NULL
2	NULL
%	NULL
Hepes-buffered	NULL
saline	NULL
,	NULL
allowed	NULL
to	NULL
precipitate	NULL
for	NULL
20	NULL
min	NULL
at	NULL
20°C	NULL
,	NULL
and	NULL
distributed	NULL
evenly	NULL
over	NULL
a	NULL
10-cm	NULL
plate	NULL
of	NULL
cells	NULL
.	NULL

After	NULL
6	NULL
h	NULL
the	NULL
medium	NULL
was	NULL
aspirated	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
shocked	NULL
with	NULL
2	NULL
ml	NULL
of	NULL
10	NULL
%	NULL
DMSO	NULL
in	NULL
PBS	NULL
for	NULL
3	NULL
min	NULL
at	NULL
20°C	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
5	NULL
ml	NULL
PBS	NULL
,	NULL
and	NULL
fed	NULL
with	NULL
10	NULL
ml	NULL
of	NULL
complete	NULL
medium	NULL
containing	NULL
the	NULL
indicated	NULL
concentration	NULL
of	NULL
dexamethasone	NULL
.	NULL

Complete	NULL
medium	NULL
containing	NULL
dexamethasone	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
was	NULL
changed	NULL
at	NULL
24	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
harvested	NULL
at	NULL
48	NULL
h	NULL
,	NULL
lysed	NULL
by	NULL
freezing	NULL
and	NULL
thawing	NULL
in	NULL
0.25	NULL
M	NULL
Tris	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Functional	NULL
assays	NULL
of	NULL
expressed	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

Specific	NULL
binding	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
to	NULL
wild-type	NULL
and	NULL
mutant	NULL
hGR	NULL
expressed	NULL
in	NULL
COS-1	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
dextran-coated	NULL
charcoal	NULL
method	NULL
(	NULL
26	NULL
)	NULL
.	NULL

About	NULL
200	NULL
ug	NULL
of	NULL
cytosolic	NULL
protein	NULL
was	NULL
incubated	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
0.1	NULL
ml	NULL
TEDGM	NULL
buffer	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
at	NULL
concentrations	NULL
from	NULL
0.1	NULL
to	NULL
25	NULL
nM	NULL
at	NULL
4°C	NULL
for	NULL
16	NULL
h	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
a	NULL
1,000-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
dexamethasone	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
K	NULL
,	NULL
of	NULL
the	NULL
hGR	NULL
for	NULL
cortisol	NULL
,	NULL
binding	NULL
was	NULL
performed	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
equal	NULL
to	NULL
its	NULL
Malchoff	NULL
,	NULL
Brufsky	NULL
,	NULL
Reardon	NULL
,	NULL
McDermott	NULL
,	NULL
Javier	NULL
,	NULL
Bergh	NULL
,	NULL
Rowe	NULL
,	NULL
and	NULL
Malchoff	NULL
K	NULL
,	NULL
,	NULL
and	NULL
cortisol	NULL
concentrations	NULL
from	NULL
3	NULL
to	NULL
1,000	NULL
nM	NULL
.	NULL

To	NULL
separate	NULL
bound	NULL
from	NULL
free	NULL
ligand	NULL
,	NULL
50	NULL
gl	NULL
of	NULL
a	NULL
solution	NULL
containing	NULL
1	NULL
%	NULL
charcoal	NULL
and	NULL
0.01	NULL
%	NULL
dextran	NULL
was	NULL
mixed	NULL
with	NULL
the	NULL
binding	NULL
reaction	NULL
and	NULL
,	NULL
after	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
the	NULL
mixture	NULL
was	NULL
centrifuged	NULL
for	NULL
2	NULL
min	NULL
on	NULL
a	NULL
microcentrifuge	NULL
.	NULL

The	NULL
super-natant	NULL
was	NULL
assayed	NULL
on	NULL
a	NULL
liquid-scintillation	NULL
counter	NULL
.	NULL

Specific	NULL
binding	NULL
was	NULL
calculated	NULL
by	NULL
subtracting	NULL
nonspecific	NULL
binding	NULL
from	NULL
total	NULL
binding	NULL
and	NULL
the	NULL
results	NULL
were	NULL
analyzed	NULL
by	NULL
Scatchard	NULL
analysis	NULL
.	NULL

The	NULL
K	NULL
,	NULL
for	NULL
cortisol	NULL
was	NULL
calculated	NULL
from	NULL
the	NULL
concentration	NULL
of	NULL
cortisol	NULL
required	NULL
to	NULL
inhibit	NULL
[	NULL
+H	NULL
]	NULL
Dex	NULL
binding	NULL
by	NULL
50	NULL
%	NULL
and	NULL
equilibrium	NULL
binding	NULL
equations	NULL
for	NULL
a	NULL
competitive	NULL
inhibitor	NULL
(	NULL
27	NULL
)	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
the	NULL
diffusion	NULL
method	NULL
of	NULL
Eastman	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
final	NULL
reaction	NULL
mixture	NULL
contains	NULL
125	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
=	NULL
7.8	NULL
)	NULL
,	NULL
1.25	NULL
mM	NULL
chloramphenicol	NULL
,	NULL
and	NULL
0.28	NULL
gM	NULL
acetyl	NULL
CoA	NULL
(	NULL
1.4	NULL
Ci/mmol	NULL
!	NULL
)	NULL

in	NULL
a	NULL
volume	NULL
of	NULL
250	NULL
Ll	NULL
.	NULL

The	NULL
cytosols	NULL
from	NULL
three	NULL
separate	NULL
transfection	NULL
experiments	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
dexamethasone	NULL
in	NULL
triplicate	NULL
and	NULL
assayed	NULL
.	NULL

Results	NULL
Fig	NULL
.	NULL

3	NULL
shows	NULL
the	NULL
Scatchard	NULL
analysis	NULL
of	NULL
the	NULL
binding	NULL
of	NULL
[	NULL
+H	NULL
JDex	NULL
to	NULL
intact	NULL
MNL	NULL
hGR	NULL
of	NULL
the	NULL
mother	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

The	NULL
normal	NULL
range	NULL
(	NULL
mean+2	NULL
SD	NULL
)	NULL
for	NULL
the	NULL
K	NULL
,	NULL
is	NULL
1.4-3.4	NULL
nM	NULL
,	NULL
and	NULL
the	NULL
normal	NULL
range	NULL
for	NULL
maximum	NULL
binding	NULL
capacity	NULL
is	NULL
5.3-7.7	NULL
fmol	NULL
/	NULL
10°	NULL
cells	NULL
.	NULL

The	NULL
K	NULL
,	NULL
derived	NULL
for	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
his	NULL
mother	NULL
were	NULL
6.4+0.8	NULL
(	NULL
mean+SEM	NULL
;	NULL
n	NULL
=	NULL
4	NULL
)	NULL
and	NULL
6.2+1.2	NULL
nM	NULL
(	NULL
mean+SEM	NULL
;	NULL
n	NULL
=	NULL
3	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
maximum	NULL
binding	NULL
capacities	NULL
are	NULL
6.5+0.5	NULL
and	NULL
5.7+0.7	NULL
fmol	NULL
/	NULL
10®	NULL
cells	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
dissociation	NULL
constants	NULL
of	NULL
both	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
his	NULL
mother	NULL
were	NULL
significantly	NULL
different	NULL
from	NULL
normal	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
and	NULL
the	NULL
maximum	NULL
binding	NULL
capacities	NULL
were	NULL
within	NULL
the	NULL
normal	NULL
range	NULL
.	NULL

The	NULL
dissociation	NULL
constants	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
his	NULL
mother	NULL
were	NULL
not	NULL
significantly	NULL
different	NULL
from	NULL
each	NULL
other	NULL
.	NULL

Using	NULL
the	NULL
PCR	NULL
,	NULL
we	NULL
amplified	NULL
in	NULL
four	NULL
overlapping	NULL
segments	NULL
the	NULL
entire	NULL
cDNA	NULL
coding	NULL
for	NULL
the	NULL
hGR	NULL
from	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
from	NULL
two	NULL
unrelated	NULL
and	NULL
unaffected	NULL
controls	NULL
.	NULL

The	NULL
976-bp	NULL
fragment	NULL
carried	NULL
the	NULL
coding	NULL
region	NULL
for	NULL
the	NULL
entire	NULL
glucocorticoid-binding	NULL
domain	NULL
and	NULL
the	NULL
506-bp	NULL
fragment	NULL
carried	NULL
the	NULL
coding	NULL
region	NULL
for	NULL
the	NULL
entire	NULL
DNA-binding	NULL
domain	NULL
.	NULL

All	NULL
samples	NULL
demonstrated	NULL
a	NULL
specific	NULL
DNA	NULL
fragment	NULL
of	NULL
appropriate	NULL
molecular	NULL
weight	NULL
after	NULL
amplification	NULL
.	NULL

All	NULL
four	NULL
fragments	NULL
were	NULL
subcloned	NULL
and	NULL
entirely	NULL
sequenced	NULL
.	NULL

Sequencing	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
's	NULL
hGR	NULL
cDNA	NULL
fragment	NULL
demonstrated	NULL
two	NULL
A	NULL
for	NULL
G	NULL
substitutions	NULL
not	NULL
present	NULL
in	NULL
a	NULL
cloned	NULL
4	NULL
Figure	NULL
3	NULL
.	NULL

Scatchard	NULL
analysis	NULL
of	NULL
[	NULL
+H	NULL
]	NULL
Dex	NULL
binding	NULL
to	NULL
hGR	NULL
of	NULL
intact	NULL
MNL	NULL
from	NULL
the	NULL
mother	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

Binding	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
to	NULL
the	NULL
hGR	NULL
of	NULL
intact	NULL
MNL	NULL
obtained	NULL
from	NULL
the	NULL
mother	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
12	NULL
unrelated	NULL
control	NULL
subjects	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
.	NULL

The	NULL
Scatchard	NULL
analysis	NULL
of	NULL
these	NULL
results	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
the	NULL
mother	NULL
's	NULL
MNL	NULL
hGR	NULL
is	NULL
represented	NULL
by	NULL
the	NULL
solid	NULL
squares	NULL
.	NULL

The	NULL
shaded	NULL
area	NULL
represents	NULL
the	NULL
95	NULL
%	NULL
confidence	NULL
limits	NULL
(	NULL
mean+2	NULL
SD	NULL
)	NULL
of	NULL
the	NULL
control	NULL
binding	NULL
.	NULL

The	NULL
95	NULL
%	NULL
confidence	NULL
intervals	NULL
of	NULL
the	NULL
slopes	NULL
are	NULL
reported	NULL
in	NULL
the	NULL
results	NULL
.	NULL

Bound	NULL
Free	NULL
0	NULL
0	NULL
4	NULL
8	NULL
[	NULL
°H	NULL
]	NULL
Dexamethasone	NULL
Bound	NULL
cells	NULL
)	NULL
hGR	NULL
cDNA	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
A	NULL
for	NULL
G	NULL
substitution	NULL
at	NULL
nucleotide	NULL
1,011	NULL
was	NULL
found	NULL
in	NULL
all	NULL
eight	NULL
clones	NULL
from	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
changes	NULL
the	NULL
codon	NULL
for	NULL
amino	NULL
acid	NULL
293	NULL
from	NULL
AAG	NULL
to	NULL
AAA	NULL
.	NULL

Both	NULL
these	NULL
codons	NULL
predict	NULL
a	NULL
lysine	NULL
in	NULL
this	NULL
position	NULL
in	NULL
the	NULL
final	NULL
protein	NULL
sequence	NULL
.	NULL

Therefore	NULL
,	NULL
this	NULL
substitution	NULL
is	NULL
not	NULL
expected	NULL
to	NULL
change	NULL
the	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
hGR	NULL
.	NULL

A	NULL
second	NULL
A	NULL
for	NULL
G	NULL
substitution	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
's	NULL
hGR	NULL
cDNA	NULL
was	NULL
identified	NULL
at	NULL
nucleotide	NULL
2,317	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

This	NULL
alteration	NULL
was	NULL
present	NULL
in	NULL
nine	NULL
of	NULL
nine	NULL
independent	NULL
pBS-hGR	NULL
recombinant	NULL
plasmids	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
A	NULL
at	NULL
position	NULL
2,317	NULL
was	NULL
the	NULL
only	NULL
nucleotide	NULL
present	NULL
in	NULL
directly	NULL
sequenced	NULL
PCR	NULL
products	NULL
from	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

The	NULL
mutation	NULL
was	NULL
not	NULL
present	NULL
in	NULL
nine	NULL
of	NULL
nine	NULL
pBS-hGR	NULL
recombinant	NULL
plasmids	NULL
sequenced	NULL
from	NULL
the	NULL
two	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
,	NULL
both	NULL
of	NULL
which	NULL
demonstrated	NULL
the	NULL
normal	NULL
G	NULL
at	NULL
this	NULL
position	NULL
.	NULL

The	NULL
A	NULL
for	NULL
G	NULL
substitution	NULL
at	NULL
position	NULL
2,317	NULL
predicts	NULL
an	NULL
alteration	NULL
in	NULL
codon	NULL
729	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
from	NULL
GTT	NULL
to	NULL
ATT	NULL
.	NULL

This	NULL
would	NULL
change	NULL
amino	NULL
acid	NULL
729	NULL
from	NULL
valine	NULL
to	NULL
isoleucine	NULL
when	NULL
the	NULL
mRNA	NULL
is	NULL
expressed	NULL
as	NULL
protein	NULL
.	NULL

No	NULL
other	NULL
mutations	NULL
were	NULL
found	NULL
.	NULL

We	NULL
next	NULL
PCR-amplified	NULL
a	NULL
311-bp	NULL
fragment	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
from	NULL
the	NULL
mother	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
a	NULL
normal	NULL
control	NULL
.	NULL

This	NULL
cDNA	NULL
fragment	NULL
was	NULL
selected	NULL
to	NULL
include	NULL
the	NULL
site	NULL
of	NULL
the	NULL
mutation	NULL
at	NULL
position	NULL
2,317	NULL
.	NULL

The	NULL
mother	NULL
's	NULL
cDNA	NULL
was	NULL
found	NULL
to	NULL
have	NULL
both	NULL
a	NULL
G	NULL
and	NULL
an	NULL
A	NULL
at	NULL
position	NULL
2,317	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
A	NULL
was	NULL
present	NULL
in	NULL
4	NULL
of	NULL
10	NULL
recombinant	NULL
pBS-hGR	NULL
plasmids	NULL
,	NULL
and	NULL
the	NULL
G	NULL
was	NULL
present	NULL
in	NULL
the	NULL
remaining	NULL
6	NULL
recombinant	NULL
pBS-hGR	NULL
plasmids	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
mother	NULL
's	NULL
cDNA	NULL
was	NULL
found	NULL
to	NULL
have	NULL
a	NULL
G/A	NULL
doublet	NULL
at	NULL
position	NULL
2,317	NULL
when	NULL
the	NULL
311-bp	NULL
hGR	NULL
cDNA	NULL
fragment	NULL
was	NULL
directly	NULL
sequenced	NULL
after	NULL
PCR	NULL
amplification	NULL
.	NULL

The	NULL
mutation	NULL
was	NULL
not	NULL
present	NULL
in	NULL
seven	NULL
of	NULL
seven	NULL
pBS-hGR	NULL
recombinant	NULL
plasmids	NULL
sequenced	NULL
from	NULL
the	NULL
unaffected	NULL
controls	NULL
.	NULL

Fig	NULL
.	NULL

5	NULL
is	NULL
an	NULL
example	NULL
of	NULL
the	NULL
restriction	NULL
enzyme	NULL
analysis	NULL
of	NULL
the	NULL
amplified	NULL
genomic	NULL
DNA	NULL
from	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
one	NULL
normal	NULL
control	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
a	NULL
96-bp	NULL
fragment	NULL
is	NULL
obtained	NULL
from	NULL
the	NULL
PCR	NULL
amplification	NULL
.	NULL

The	NULL
fragment	NULL
amplified	NULL
from	NULL
the	NULL
index	NULL
subject	NULL
is	NULL
cut	NULL
completely	NULL
by	NULL
HphI	NULL
to	NULL
yield	NULL
a	NULL
60-bp	NULL
fragment	NULL
,	NULL
but	NULL
this	NULL
fragment	NULL
is	NULL
not	NULL
cut	NULL
by	NULL
BslI	NULL
.	NULL

This	NULL
demonstrates	NULL
that	NULL
his	NULL
genomic	NULL
DNA	NULL
is	NULL
homozygous	NULL
for	NULL
the	NULL
A	NULL
for	NULL
G	NULL
substitution	NULL
at	NULL
cDNA	NULL
nucleotide	NULL
2,317	NULL
,	NULL
which	NULL
creates	NULL
a	NULL
new	NULL
HphlI	NULL
site	NULL
and	NULL
causes	NULL
a	NULL
loss	NULL
of	NULL
the	NULL
BslI	NULL
site	NULL
.	NULL

The	NULL
fragment	NULL
amplified	NULL
from	NULL
the	NULL
control	NULL
subject	NULL
is	NULL
cut	NULL
completely	NULL
by	NULL
BslI	NULL
to	NULL
yield	NULL
a	NULL
72-bp	NULL
fragment	NULL
,	NULL
but	NULL
this	NULL
fragment	NULL
is	NULL
not	NULL
cut	NULL
by	NULL
HphlI	NULL
.	NULL

Analysis	NULL
of	NULL
genomic	NULL
DNA	NULL
from	NULL
20	NULL
unrelated	NULL
controls	NULL
gave	NULL
this	NULL
same	NULL
result	NULL
.	NULL

Therefore	NULL
,	NULL
both	NULL
alleles	NULL
of	NULL
each	NULL
control	NULL
genomic	NULL
DNA	NULL
have	NULL
a	NULL
G	NULL
at	NULL
nucleotide	NULL
2,317	NULL
,	NULL
not	NULL
an	NULL
A	NULL
.	NULL

Not	NULL
shown	NULL
is	NULL
the	NULL
fragment	NULL
amplified	NULL
from	NULL
the	NULL
mother	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
,	NULL
which	NULL
is	NULL
cut	NULL
partially	NULL
by	NULL
both	NULL
enzymes	NULL
,	NULL
indicating	NULL
that	NULL
she	NULL
is	NULL
heterozygous	NULL
and	NULL
carries	NULL
a	NULL
copy	NULL
of	NULL
both	NULL
the	NULL
mutant	NULL
and	NULL
wild-type	NULL
alleles	NULL
.	NULL

The	NULL
expression	NULL
vector	NULL
for	NULL
the	NULL
hGR-Ile	NULL
729	NULL
was	NULL
prepared	NULL
as	NULL
described	NULL
in	NULL
the	NULL
Methods	NULL
section	NULL
,	NULL
and	NULL
the	NULL
wild-type	NULL
hGR	NULL
and	NULL
hGR-Ile	NULL
729	NULL
were	NULL
expressed	NULL
in	NULL
tissue	NULL
culture	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
is	NULL
an	NULL
example	NULL
of	NULL
the	NULL
Scatchard	NULL
analysis	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
binding	NULL
to	NULL
the	NULL
wild-type	NULL
hGR	NULL
and	NULL
mutant	NULL
hGR-lIle	NULL
729	NULL
that	NULL
had	NULL
been	NULL
expressed	NULL
in	NULL
COS-1	NULL
cells	NULL
.	NULL

It	NULL
illustrates	NULL
the	NULL
decreased	NULL
affinity	NULL
of	NULL
hGR	NULL
Ile-729	NULL
for	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
.	NULL

The	NULL
binding	NULL
analysis	NULL
was	NULL
performed	NULL
in	NULL
duplicate	NULL
on	NULL
the	NULL
cytosols	NULL
from	NULL
four	NULL
separate	NULL
transfection	NULL
experiments	NULL
.	NULL

The	NULL
dissociation	NULL
constants	NULL
for	NULL
the	NULL
wild-type	NULL
hGR	NULL
and	NULL
hGR-Ile	NULL
729	NULL
were	NULL
0.799+0.068	NULL
and	NULL
1.54+0.06	NULL
nM	NULL
(	NULL
mean+SEM	NULL
,	NULL
n	NULL
=	NULL
4	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
maximum	NULL
binding	NULL
capacities	NULL
were	NULL
1,030+160	NULL
and	NULL
1,1	NULL
30+2	NULL
10	NULL
fmol	NULL
/	NULL
mg	NULL
protein	NULL
(	NULL
P	NULL
=	NULL
NS	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
dissociation	NULL
constants	NULL
of	NULL
the	NULL
wild-type	NULL
hGR	NULL
and	NULL
hGR-lle	NULL
729	NULL
for	NULL
cortisol	NULL
were	NULL
11.2+2.8	NULL
and	NULL
32.2+8.4	NULL
nM	NULL
,	NULL
respectively	NULL
(	NULL
n	NULL
=	NULL
3	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

Glucocorticoid	NULL
Receptor	NULL
Mutation	NULL
1921	NULL
A	NULL
G	NULL
A	NULL
T	NULL
C	NULL
G	NULL
A	NULL
T	NULL
C	NULL
will	NULL
«	NULL
omit	NULL
mad	NULL
T	NULL
sivas	NULL
T	NULL
«	NULL
mn	NULL
j	NULL
[	NULL
(	NULL
CM	NULL
G	NULL
w	NULL
G	NULL
cname	NULL
A	NULL
aan	NULL
A	NULL
2	NULL
comme	NULL
A	NULL
gente	NULL
A	NULL
G	NULL
(	NULL
T3	NULL
«	NULL
gm	NULL
(	NULL
T3	NULL
f	NULL
«	NULL
awan	NULL
T	NULL
#	NULL
-	NULL
G	NULL
t	NULL
G	NULL
-	NULL
a**	NULL
mute	NULL
>	NULL
A	NULL
1	NULL
t	NULL
woes	NULL
H	NULL
®	NULL
1	NULL
6	NULL
®	NULL
c	NULL
&	NULL
*	NULL
fe	NULL
``	NULL
s	NULL
CCB	NULL
)	NULL
C	NULL
Mother	NULL
's	NULL
Normal	NULL
Sequence	NULL
Fibroblast	NULL
Normal	NULL
Normal	NULL
Allele	NULL
MNL	NULL
60	NULL
%	NULL
B	NULL
ATG	NULL
CAT	NULL
GAA	NULL
GTG	NULL
GTT	NULL
GAA	NULL
AAT	NULL
CTC	NULL
CTT	NULL
Met	NULL
His	NULL
Glu	NULL
Val	NULL
Val	NULL
Glu	NULL
Asn	NULL
Leu	NULL
Leu	NULL
Normal	NULL
Sequence	NULL
Amino	NULL
Acid	NULL
Position	NULL
725	NULL
729	NULL
733	NULL
ATG	NULL
CAT	NULL
GAA	NULL
GTG	NULL
ATT	NULL
Gaa	NULL
AAT	NULL
CTC	NULL
CTT	NULL
Mutant	NULL
Sequence	NULL
Met	NULL
His	NULL
Glu	NULL
Val	NULL
lle	NULL
Glu	NULL
Asn	NULL
Leu	NULL
Leu	NULL
The	NULL
stimulation	NULL
of	NULL
CAT	NULL
activity	NULL
by	NULL
dexamethasone	NULL
in	NULL
CV-1	NULL
cells	NULL
cotransfected	NULL
with	NULL
pMTVCAT	NULL
and	NULL
expression	NULL
vectors	NULL
for	NULL
the	NULL
wild-type	NULL
hGR	NULL
and	NULL
hGR-lle	NULL
729	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

The	NULL
mean	NULL
shift	NULL
in	NULL
the	NULL
concentration	NULL
of	NULL
dexamethasone	NULL
required	NULL
for	NULL
half	NULL
maximal	NULL
stimulation	NULL
of	NULL
CAT	NULL
activity	NULL
was	NULL
4.0+0.9-fold	NULL
(	NULL
P	NULL
Index	NULL
Subject	NULL
MW	NULL
_	NULL
Control	NULL
I	NULL
1	NULL
F	NULL
1	NULL
_	NULL
-	NULL
£	NULL
T	NULL
oC	NULL
a	NULL
a	NULL
w	NULL
a	NULL
°	NULL
m	NULL
ITC	NULL
o	NULL
m	NULL
IC	NULL
-ilfem	NULL
96	NULL
bp	NULL
«	NULL
al-	NULL
72	NULL
bp	NULL
--	NULL
60	NULL
bp	NULL
Figure	NULL
5	NULL
.	NULL

Cleavage	NULL
of	NULL
PCR-amplified	NULL
genomic	NULL
DNA	NULL
with	NULL
BslI	NULL
and	NULL
HphlI	NULL
.	NULL

Genomic	NULL
DNA	NULL
from	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
a	NULL
normal	NULL
control	NULL
was	NULL
PCR	NULL
amplified	NULL
using	NULL
primers	NULL
RE2	NULL
and	NULL
RE3	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
.	NULL

Equal	NULL
aliquots	NULL
were	NULL
incubated	NULL
without	NULL
restriction	NULL
enzymes	NULL
,	NULL
with	NULL
Bsl1	NULL
,	NULL
or	NULL
HphlI	NULL
,	NULL
as	NULL
indicated	NULL
and	NULL
analyzed	NULL
on	NULL
with	NULL
6	NULL
%	NULL
PAGE	NULL
and	NULL
ethidium	NULL
bromide	NULL
staining	NULL
.	NULL

MW	NULL
indicates	NULL
molecular	NULL
weight	NULL
markers	NULL
.	NULL

PCR	NULL
amplification	NULL
of	NULL
the	NULL
genomic	NULL
DNA	NULL
yielded	NULL
a	NULL
96-bp	NULL
fragment	NULL
using	NULL
either	NULL
genomic	NULL
DNA	NULL
as	NULL
template	NULL
.	NULL

The	NULL
PCR-amplified	NULL
DNA	NULL
from	NULL
the	NULL
index	NULL
subject	NULL
was	NULL
cleaved	NULL
completely	NULL
with	NULL
HphI	NULL
to	NULL
yield	NULL
a	NULL
60-bp	NULL
fragment	NULL
but	NULL
was	NULL
not	NULL
cleaved	NULL
by	NULL
BslI	NULL
.	NULL

The	NULL
PCR-amplified	NULL
DNA	NULL
from	NULL
this	NULL
and	NULL
19	NULL
other	NULL
unrelated	NULL
control	NULL
subjects	NULL
was	NULL
cleaved	NULL
completely	NULL
with	NULL
BslI	NULL
to	NULL
yield	NULL
a	NULL
72-bp	NULL
fragment	NULL
but	NULL
was	NULL
not	NULL
cleaved	NULL
by	NULL
HphlI	NULL
.	NULL

1922	NULL
Sousa	NULL
1	NULL
Cummed	NULL
G	NULL
meses	NULL
A	NULL
A	NULL
anar	NULL
C	NULL
-	NULL
eee	NULL
T	NULL
``	NULL
@	NULL
G	NULL
>	NULL
A	NULL
ann	NULL
.	NULL

i	NULL
Plana	NULL
;	NULL
Figure	NULL
4	NULL
.	NULL

Sequence	NULL
of	NULL
o	NULL
**	NULL
‘	NULL
the	NULL
hGR	NULL
mutation	NULL
.	NULL

(	NULL
4	NULL
)	NULL
A	NULL
i	NULL
Experimental	NULL
result	NULL
.	NULL

Se-s	NULL
quencing	NULL
of	NULL
recombi-f	NULL
nant	NULL
plasmids	NULL
was	NULL
per-Stairs	NULL
;	NULL
Patient	NULL
's	NULL
formed	NULL
as	NULL
described	NULL
in	NULL
Mutant	NULL
Sequence	NULL
Methods	NULL
,	NULL
and	NULL
the	NULL
region	NULL
99	NULL
of	NULL
interest	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
Allele	NULL
clones	NULL
X	NULL
40	NULL
%	NULL
altered	NULL
nucleotide	NULL
at	NULL
position	NULL
2,317	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
arrow	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Amino	NULL
acid	NULL
and	NULL
cDNA	NULL
sequences	NULL
immediately	NULL
surrounding	NULL
the	NULL
mutation	NULL
.	NULL

The	NULL
mutation	NULL
changes	NULL
the	NULL
valine	NULL
at	NULL
position	NULL
729	NULL
to	NULL
isoleu-cine	NULL
.	NULL

<	NULL
0.05	NULL
)	NULL
,	NULL
when	NULL
the	NULL
mutant	NULL
hGR-Ile	NULL
729	NULL
expression	NULL
vector	NULL
was	NULL
substituted	NULL
for	NULL
the	NULL
wild-type	NULL
hGR	NULL
expression	NULL
vector	NULL
.	NULL

The	NULL
maximum	NULL
CAT	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
30	NULL
nM	NULL
dexamethasone	NULL
increased	NULL
linearly	NULL
with	NULL
the	NULL
log	NULL
of	NULL
the	NULL
amount	NULL
of	NULL
the	NULL
hGR	NULL
and	NULL
hGR-Ile	NULL
729	NULL
expression	NULL
vectors	NULL
transfected	NULL
up	NULL
to	NULL
10	NULL
ug	NULL
of	NULL
expression	NULL
vector	NULL
.	NULL

Discussion	NULL
Fig	NULL
.	NULL

8	NULL
summarizes	NULL
the	NULL
sequencing	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
's	NULL
hGR	NULL
cDNA	NULL
and	NULL
indicates	NULL
the	NULL
relative	NULL
cDNA	NULL
and	NULL
amino	NULL
acid	NULL
location	NULL
of	NULL
the	NULL
mutation	NULL
at	NULL
hGR	NULL
cDNA	NULL
nucleotide	NULL
2,317	NULL
.	NULL

This	NULL
A	NULL
for	NULL
G	NULL
substitution	NULL
predicts	NULL
the	NULL
substitution	NULL
of	NULL
an	NULL
isoleucine	NULL
for	NULL
a	NULL
valine	NULL
at	NULL
hGR	NULL
amino	NULL
acid	NULL
729	NULL
,	NULL
which	NULL
is	NULL
located	NULL
in	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
.	NULL

Not	NULL
shown	NULL
is	NULL
the	NULL
A	NULL
for	NULL
G	NULL
substitu-	NULL
Figure	NULL
6	NULL
.	NULL

Scatchard	NULL
analysis	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
binding	NULL
to	NULL
the	NULL
wild-type	NULL
hGR	NULL
and	NULL
hGR-Ile	NULL
729	NULL
.	NULL

COS-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild-type	NULL
hGR	NULL
or	NULL
hGR-Ile	NULL
729	NULL
expression	NULL
vector	NULL
using	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
,	NULL
and	NULL
the	NULL
cytosol	NULL
was	NULL
assayed	NULL
for	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
binding	NULL
.	NULL

Cytosol	NULL
from	NULL
control	NULL
COS-1	NULL
cells	NULL
transfected	NULL
with	NULL
pBS	NULL
KS+	NULL
DNA	NULL
does	NULL
not	NULL
bind	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
,	NULL
indicating	NULL
an	NULL
absence	NULL
of	NULL
hGR	NULL
in	NULL
COS-1	NULL
cells	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
are	NULL
of	NULL
a	NULL
single	NULL
experiment	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

Four	NULL
separate	NULL
transfection	NULL
experiments	NULL
using	NULL
four	NULL
different	NULL
transfection	NULL
products	NULL
for	NULL
both	NULL
the	NULL
hGR	NULL
and	NULL
hGR-Ile	NULL
729	NULL
were	NULL
assayed	NULL
in	NULL
duplicate	NULL
and	NULL
the	NULL
apparent	NULL
dissociation	NULL
constants	NULL
were	NULL
0.799+0.068	NULL
and	NULL
1.54+0.06	NULL
nM	NULL
(	NULL
mean+SEM	NULL
)	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

B/F	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
Bound	NULL
{	NULL
fmol/mg	NULL
protein	NULL
)	NULL
Malchoff	NULL
,	NULL
Brufsky	NULL
,	NULL
Reardon	NULL
,	NULL
McDermott	NULL
,	NULL
Javier	NULL
,	NULL
Bergh	NULL
,	NULL
Rowe	NULL
,	NULL
and	NULL
Malchoff	NULL
Figure	NULL
7	NULL
.	NULL

Stimulation	NULL
of	NULL
CAT	NULL
activity	NULL
by	NULL
dexamethasone	NULL
.	NULL

CV-1	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
MTV-CAT	NULL
and	NULL
either	NULL
hGR	NULL
or	NULL
hGR-Ile	NULL
729	NULL
expression	NULL
vectors	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
method	NULL
and	NULL
incubated	NULL
for	NULL
48	NULL
h	NULL
with	NULL
dexamethasone	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
.	NULL

Super-natants	NULL
from	NULL
the	NULL
cells	NULL
were	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
.	NULL

The	NULL
mean	NULL
activities	NULL
from	NULL
three	NULL
separate	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
are	NULL
plotted	NULL
.	NULL

The	NULL
CAT	NULL
activity	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
hGR	NULL
and	NULL
hGR-lle	NULL
729	NULL
is	NULL
significantly	NULL
different	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
at	NULL
dexamethasone	NULL
concentrations	NULL
of	NULL
0.03	NULL
,	NULL
0.1	NULL
,	NULL
0.3	NULL
,	NULL
1.0	NULL
,	NULL
and	NULL
3.0	NULL
nM	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
dexamethasone	NULL
required	NULL
for	NULL
half	NULL
maximal	NULL
stimulation	NULL
of	NULL
CAT	NULL
activity	NULL
was	NULL
4.0+0.9-fold	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
greater	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
hGR-Ile	NULL
729	NULL
expression	NULL
vector	NULL
than	NULL
when	NULL
they	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
hGR	NULL
expression	NULL
vector	NULL
.	NULL

Maximum	NULL
CAT	NULL
activity	NULL
was	NULL
250+35	NULL
pmol/mg	NULL
protein	NULL
per	NULL
h.	NULL
No	NULL
CAT	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dexamethasone	NULL
or	NULL
if	NULL
the	NULL
expression	NULL
vector	NULL
for	NULL
MTV-CAT	NULL
was	NULL
transfected	NULL
with	NULL
pBS	NULL
KS+	NULL
.	NULL

100	NULL
&	NULL
o	NULL
-e	NULL
.	NULL

'/	NULL
.	NULL

®	NULL
n	NULL
hGR	NULL
50	NULL
mest	NULL
/	NULL
/	NULL
n	NULL
'	NULL
hGR	NULL
(	NULL
3	NULL
/	NULL
Ile	NULL
729	NULL
/	NULL
a	NULL
e	NULL
a	NULL
|	NULL
B	NULL
o	NULL
_	NULL
.03	NULL
0.3	NULL
3.0	NULL
30	NULL
log	NULL
Dex	NULL
(	NULL
nM	NULL
)	NULL
%	NULL
CAT	NULL
Activity	NULL
tion	NULL
at	NULL
nucleotide	NULL
1,011	NULL
.	NULL

This	NULL
mutation	NULL
does	NULL
not	NULL
predict	NULL
a	NULL
change	NULL
in	NULL
the	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
hGR	NULL
and	NULL
therefore	NULL
is	NULL
not	NULL
expected	NULL
to	NULL
cause	NULL
cortisol	NULL
resistance	NULL
.	NULL

The	NULL
entire	NULL
hGR	NULL
cDNA	NULL
was	NULL
sequenced	NULL
and	NULL
no	NULL
other	NULL
mutations	NULL
were	NULL
found	NULL
.	NULL

The	NULL
evidence	NULL
in	NULL
this	NULL
manuscript	NULL
supports	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
mutation	NULL
at	NULL
nucleotide	NULL
2,317	NULL
is	NULL
the	NULL
cause	NULL
of	NULL
decreased	NULL
dexamethasone-binding	NULL
affinity	NULL
and	NULL
subsequently	NULL
primary	NULL
cortisol	NULL
resistance	NULL
in	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

The	NULL
studies	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
binding	NULL
to	NULL
the	NULL
hGR	NULL
of	NULL
the	NULL
intact	NULL
MNL	NULL
shows	NULL
an	NULL
affinity	NULL
abnormality	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
from	NULL
both	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
his	NULL
mother	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
cortisol	NULL
resistance	NULL
is	NULL
an	NULL
inherited	NULL
defect	NULL
and	NULL
has	NULL
not	NULL
arisen	NULL
as	NULL
a	NULL
new	NULL
mutation	NULL
in	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

Since	NULL
the	NULL
affinity	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
is	NULL
affected	NULL
,	NULL
an	NULL
abnormality	NULL
in	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
is	NULL
expected	NULL
.	NULL

The	NULL
G	NULL
to	NULL
A	NULL
missense	NULL
point	NULL
mutation	NULL
at	NULL
nucleotide	NULL
2,317	NULL
was	NULL
not	NULL
an	NULL
artifact	NULL
of	NULL
our	NULL
reverse	NULL
transcription	NULL
and	NULL
/or	NULL
amplification	NULL
procedures	NULL
,	NULL
since	NULL
it	NULL
was	NULL
found	NULL
in	NULL
two	NULL
family	NULL
members	NULL
and	NULL
not	NULL
in	NULL
normal	NULL
controls	NULL
.	NULL

Restriction	NULL
enzyme	NULL
analysis	NULL
of	NULL
the	NULL
PCR-amplified	NULL
genomic	NULL
DNA	NULL
from	NULL
the	NULL
index	NULL
subject	NULL
,	NULL
his	NULL
mother	NULL
,	NULL
and	NULL
normal	NULL
controls	NULL
provides	NULL
further	NULL
evidence	NULL
that	NULL
the	NULL
mutation	NULL
is	NULL
not	NULL
an	NULL
artifact	NULL
of	NULL
our	NULL
procedures	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
the	NULL
mutation	NULL
in	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
his	NULL
mother	NULL
in	NULL
a	NULL
specific	NULL
and	NULL
sensitive	NULL
assay	NULL
of	NULL
genomic	NULL
DNA	NULL
.	NULL

The	NULL
mutation	NULL
was	NULL
not	NULL
found	NULL
in	NULL
20	NULL
unrelated	NULL
controls	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
index	NULL
subject	NULL
is	NULL
homozygous	NULL
for	NULL
the	NULL
mutation	NULL
at	NULL
nucleotide	NULL
2,317	NULL
.	NULL

The	NULL
only	NULL
nucleotide	NULL
found	NULL
at	NULL
position	NULL
2,317	NULL
of	NULL
his	NULL
hGR	NULL
cDNA	NULL
was	NULL
an	NULL
A	NULL
,	NULL
and	NULL
the	NULL
parents	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
are	NULL
believed	NULL
to	NULL
be	NULL
first	NULL
cousins	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
analysis	NULL
of	NULL
the	NULL
genomic	NULL
DNA	NULL
supports	NULL
the	NULL
conclusion	NULL
,	NULL
since	NULL
the	NULL
DNA	NULL
fragment	NULL
that	NULL
was	NULL
amplified	NULL
from	NULL
genomic	NULL
DNA	NULL
was	NULL
cleaved	NULL
by	NULL
HphlI	NULL
,	NULL
and	NULL
not	NULL
BslI	NULL
.	NULL

This	NULL
mutation	NULL
is	NULL
apparently	NULL
heterozygous	NULL
in	NULL
the	NULL
mother	NULL
,	NULL
since	NULL
approximately	NULL
half	NULL
of	NULL
her	NULL
hGR	NULL
cDNA	NULL
clones	NULL
had	NULL
a	NULL
G	NULL
at	NULL
position	NULL
2,317	NULL
,	NULL
and	NULL
half	NULL
had	NULL
an	NULL
A	NULL
.	NULL

The	NULL
analysis	NULL
of	NULL
the	NULL
genomic	NULL
DNA	NULL
also	NULL
supports	NULL
this	NULL
conclusion	NULL
,	NULL
since	NULL
the	NULL
amplified	NULL
DNA	NULL
could	NULL
be	NULL
partially	NULL
cut	NULL
by	NULL
both	NULL
restriction	NULL
enzymes	NULL
.	NULL

The	NULL
father	NULL
was	NULL
not	NULL
available	NULL
for	NULL
analysis	NULL
but	NULL
is	NULL
likely	NULL
to	NULL
have	NULL
contributed	NULL
the	NULL
second	NULL
mutant	NULL
allele	NULL
to	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

He	NULL
could	NULL
have	NULL
contributed	NULL
a	NULL
nonexpressed	NULL
or	NULL
null	NULL
allele	NULL
to	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

However	NULL
,	NULL
this	NULL
possibility	NULL
is	NULL
unlikely	NULL
in	NULL
light	NULL
of	NULL
the	NULL
normal	NULL
receptor-binding	NULL
capacity	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
's	NULL
hGR	NULL
,	NULL
which	NULL
implies	NULL
a	NULL
normal	NULL
amount	NULL
of	NULL
receptor	NULL
protein	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
support	NULL
the	NULL
hypothesis	NULL
that	NULL
hGR-Ile	NULL
729	NULL
is	NULL
the	NULL
cause	NULL
of	NULL
primary	NULL
cortisol	NULL
resistance	NULL
in	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

First	NULL
,	NULL
the	NULL
location	NULL
of	NULL
the	NULL
mutation	NULL
in	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
predicts	NULL
that	NULL
the	NULL
receptor	NULL
will	NULL
have	NULL
a	NULL
decreased	NULL
affinity	NULL
for	NULL
dexamethasone	NULL
,	NULL
as	NULL
we	NULL
had	NULL
observed	NULL
in	NULL
the	NULL
MNL	NULL
hGR	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

In	NULL
vitro	NULL
experiments	NULL
with	NULL
transfected	NULL
cloned	NULL
animal	NULL
and	NULL
human	NULL
hGR	NULL
cDNAs	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
terminal	NULL
250	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
receptor	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
glucocorticoid-binding	NULL
activity	NULL
,	NULL
which	NULL
can	NULL
be	NULL
altered	NULL
by	NULL
single	NULL
amino	NULL
acid	NULL
changes	NULL
(	NULL
13-15	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
identified	NULL
mutation	NULL
is	NULL
in	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
as	NULL
expected	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
decreased	NULL
dexamethasone	NULL
affinity	NULL
of	NULL
the	NULL
hGR	NULL
.	NULL

Second	NULL
,	NULL
no	NULL
other	NULL
mutation	NULL
that	NULL
predicts	NULL
a	NULL
change	NULL
in	NULL
the	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
hGR	NULL
was	NULL
found	NULL
.	NULL

Third	NULL
,	NULL
the	NULL
functional	NULL
activities	NULL
of	NULL
the	NULL
hGR-Ile	NULL
729	NULL
receptor	NULL
expressed	NULL
in	NULL
tissue	NULL
culture	NULL
were	NULL
very	NULL
similar	NULL
to	NULL
those	NULL
observed	NULL
in	NULL
vivo	NULL
.	NULL

When	NULL
expressed	NULL
in	NULL
mammalian	NULL
cells	NULL
the	NULL
hGR-Ile	NULL
729	NULL
is	NULL
functionally	NULL
abnormal	NULL
.	NULL

The	NULL
dissociation	NULL
constant	NULL
for	NULL
[	NULL
°H	NULL
]	NULL
Dex	NULL
is	NULL
about	NULL
twice	NULL
normal	NULL
.	NULL

This	NULL
corresponds	NULL
well	NULL
with	NULL
the	NULL
two-	NULL
to	NULL
threefold	NULL
increase	NULL
in	NULL
dissociation	NULL
constant	NULL
of	NULL
the	NULL
native	NULL
MNL	NULL
hGR	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
fourfold	NULL
decrease	NULL
in	NULL
the	NULL
apparent	NULL
potency	NULL
of	NULL
dexamethasone	NULL
to	NULL
stimulate	NULL
hGR-mediated	NULL
gene	NULL
transcription	NULL
corresponds	NULL
well	NULL
with	NULL
the	NULL
in	NULL
vivo	NULL
response	NULL
of	NULL
ACTH	NULL
to	NULL
dexamethasone	NULL
.	NULL

A	NULL
daily	NULL
dose	NULL
of	NULL
4	NULL
mg	NULL
of	NULL
dexamethasone	NULL
was	NULL
required	NULL
to	NULL
decrease	NULL
the	NULL
serum	NULL
cortisol	NULL
concentration	NULL
to	NULL
<	NULL
140	NULL
nmol/liter	NULL
(	NULL
5	NULL
ug/dl	NULL
)	NULL
in	NULL
the	NULL
index	NULL
subject	NULL
(	NULL
9	NULL
)	NULL
.	NULL

This	NULL
is	NULL
about	NULL
five	NULL
times	NULL
as	NULL
much	NULL
as	NULL
is	NULL
nor	NULL
DNA	NULL
_	NULL
Glucocorticoid	NULL
Binding	NULL
Binding	NULL
``	NULL
ah	NULL
.	NULL

protein	NULL
NHQ	NULL
COOH	NULL
e	NULL
1	NULL
411	NULL
489	NULL
582	NULL
T77	NULL
729	NULL
2317	NULL
133	NULL
1366	NULL
1598	NULL
1714	NULL
$	NULL
2466	NULL
|__|	NULL
cDbna	NULL
5	NULL
r	NULL
N	NULL
2	NULL
3	NULL
'	NULL
L.	NULL
ml	NULL
E	NULL
__	NULL
I	NULL
76	NULL
sequenced	NULL
cDNA	NULL
f	NULL
2490	NULL
mutant	NULL
(	NULL
ATT	NULL
)	NULL
Ile	NULL
729	NULL
wild	NULL
type	NULL
(	NULL
GTT	NULL
)	NULL
Val	NULL
729	NULL
Figure	NULL
8	NULL
.	NULL

Summary	NULL
of	NULL
the	NULL
hGR	NULL
mutation	NULL
in	NULL
relationship	NULL
to	NULL
the	NULL
hGR	NULL
functional	NULL
domains	NULL
.	NULL

The	NULL
hGR	NULL
protein	NULL
structure	NULL
is	NULL
summarized	NULL
in	NULL
the	NULL
top	NULL
bar	NULL
with	NULL
the	NULL
numbers	NULL
indicating	NULL
the	NULL
relevant	NULL
amino	NULL
acids	NULL
.	NULL

The	NULL
lower	NULL
bar	NULL
summarizes	NULL
the	NULL
hGR	NULL
cDNA	NULL
with	NULL
the	NULL
numbers	NULL
indicating	NULL
the	NULL
corresponding	NULL
nucleotides	NULL
.	NULL

The	NULL
line	NULL
below	NULL
this	NULL
indicates	NULL
the	NULL
portion	NULL
of	NULL
the	NULL
hGR	NULL
cDNA	NULL
sequenced	NULL
in	NULL
this	NULL
study	NULL
.	NULL

The	NULL
entire	NULL
hGR	NULL
coding	NULL
region	NULL
was	NULL
sequenced	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
site	NULL
of	NULL
the	NULL
hGR	NULL
mutation	NULL
that	NULL
causes	NULL
primary	NULL
cortisol	NULL
resistance	NULL
.	NULL

Glucocorticoid	NULL
Receptor	NULL
Mutation	NULL
__	NULL
1923	NULL
mally	NULL
expected	NULL
to	NULL
produce	NULL
the	NULL
same	NULL
effect	NULL
.	NULL

Fourth	NULL
,	NULL
similar	NULL
findings	NULL
have	NULL
been	NULL
demonstrated	NULL
in	NULL
other	NULL
disorders	NULL
of	NULL
steroid	NULL
hormone	NULL
resistance	NULL
.	NULL

In	NULL
another	NULL
kindred	NULL
with	NULL
primary	NULL
cortisol	NULL
resistance	NULL
,	NULL
a	NULL
single	NULL
amino	NULL
acid	NULL
change	NULL
of	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
causes	NULL
cortisol	NULL
resistance	NULL
(	NULL
11	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
single	NULL
amino	NULL
acid	NULL
alterations	NULL
of	NULL
the	NULL
human	NULL
androgen	NULL
receptor	NULL
(	NULL
29	NULL
)	NULL
and	NULL
human	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
(	NULL
30	NULL
)	NULL
cause	NULL
end	NULL
organ	NULL
resistance	NULL
syndromes	NULL
to	NULL
each	NULL
of	NULL
these	NULL
hormones	NULL
.	NULL

Fifth	NULL
,	NULL
studies	NULL
of	NULL
androgen-resistance	NULL
syndromes	NULL
have	NULL
identified	NULL
two	NULL
regions	NULL
of	NULL
the	NULL
androgen	NULL
receptor	NULL
ligand-binding	NULL
domain	NULL
that	NULL
frequently	NULL
carry	NULL
mutations	NULL
in	NULL
subjects	NULL
with	NULL
decreased	NULL
androgen	NULL
receptor	NULL
affinity	NULL
for	NULL
testosterone	NULL
and	NULL
subsequent	NULL
androgen	NULL
resistance	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
mutation	NULL
that	NULL
we	NULL
suspect	NULL
to	NULL
cause	NULL
cortisol	NULL
resistance	NULL
is	NULL
located	NULL
in	NULL
a	NULL
region	NULL
of	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
analogous	NULL
to	NULL
one	NULL
of	NULL
these	NULL
two	NULL
regions	NULL
of	NULL
the	NULL
androgen	NULL
receptor	NULL
ligand-binding	NULL
domain	NULL
.	NULL

As	NULL
in	NULL
the	NULL
androgen-resistance	NULL
model	NULL
,	NULL
a	NULL
mutation	NULL
in	NULL
this	NULL
region	NULL
of	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
causes	NULL
hormone	NULL
resistance	NULL
by	NULL
altering	NULL
the	NULL
receptor	NULL
affinity	NULL
for	NULL
its	NULL
ligand	NULL
.	NULL

Sixth	NULL
,	NULL
the	NULL
mother	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
is	NULL
heterozygous	NULL
for	NULL
the	NULL
mutation	NULL
that	NULL
the	NULL
index	NULL
subject	NULL
is	NULL
apparently	NULL
homozygous	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
expected	NULL
that	NULL
she	NULL
would	NULL
be	NULL
less	NULL
clinically	NULL
affected	NULL
than	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

Indeed	NULL
,	NULL
this	NULL
is	NULL
the	NULL
case	NULL
,	NULL
since	NULL
she	NULL
has	NULL
no	NULL
hirsutism	NULL
,	NULL
infertility	NULL
,	NULL
or	NULL
other	NULL
clinical	NULL
evidence	NULL
of	NULL
androgen	NULL
excess	NULL
.	NULL

Taken	NULL
together	NULL
these	NULL
six	NULL
lines	NULL
of	NULL
evidence	NULL
strongly	NULL
support	NULL
the	NULL
hypothesis	NULL
that	NULL
an	NULL
A	NULL
for	NULL
G	NULL
substitution	NULL
at	NULL
nucleotide	NULL
2,317	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
syndrome	NULL
of	NULL
primary	NULL
cortisol	NULL
resistance	NULL
in	NULL
the	NULL
index	NULL
subject	NULL
.	NULL

A	NULL
mutation	NULL
causing	NULL
primary	NULL
cortisol	NULL
resistance	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
one	NULL
other	NULL
kindred	NULL
.	NULL

This	NULL
mutation	NULL
was	NULL
at	NULL
a	NULL
different	NULL
position	NULL
in	NULL
the	NULL
glucocorticoid-binding	NULL
domain	NULL
and	NULL
also	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
decreased	NULL
hGR	NULL
affinity	NULL
for	NULL
glucocorticoids	NULL
.	NULL

It	NULL
was	NULL
homozygous	NULL
in	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
heterozygous	NULL
in	NULL
a	NULL
family	NULL
member	NULL
who	NULL
was	NULL
less	NULL
affected	NULL
clinically	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Interest-ingly	NULL
,	NULL
the	NULL
mutation	NULL
reported	NULL
here	NULL
is	NULL
biochemically	NULL
more	NULL
conservative	NULL
than	NULL
most	NULL
others	NULL
that	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
cause	NULL
cortisol	NULL
resistance	NULL
or	NULL
other	NULL
syndromes	NULL
of	NULL
steroid	NULL
hormone	NULL
resistance	NULL
(	NULL
11	NULL
,	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

This	NULL
very	NULL
conservative	NULL
substitution	NULL
of	NULL
a	NULL
neutral	NULL
isoleucine	NULL
for	NULL
a	NULL
neutral	NULL
valine	NULL
produces	NULL
a	NULL
surprisingly	NULL
large	NULL
change	NULL
in	NULL
receptor	NULL
affinity	NULL
for	NULL
glucocorticoids	NULL
and	NULL
a	NULL
clinical	NULL
syndrome	NULL
with	NULL
cortisol	NULL
resistance	NULL
that	NULL
is	NULL
seemingly	NULL
greater	NULL
than	NULL
anticipated	NULL
from	NULL
the	NULL
change	NULL
in	NULL
dexamethasone	NULL
binding	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
this	NULL
is	NULL
not	NULL
complete	NULL
resistance	NULL
,	NULL
since	NULL
it	NULL
can	NULL
be	NULL
overcome	NULL
by	NULL
large	NULL
amounts	NULL
of	NULL
exogenous	NULL
glucocorticoids	NULL
(	NULL
9	NULL
)	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
proposed	NULL
that	NULL
complete	NULL
resistance	NULL
may	NULL
be	NULL
incompatible	NULL
with	NULL
life	NULL
(	NULL
32	NULL
)	NULL
.	NULL

There	NULL
are	NULL
two	NULL
possible	NULL
explanations	NULL
for	NULL
the	NULL
apparent	NULL
discrepancy	NULL
between	NULL
the	NULL
dexamethasone-binding	NULL
affinity	NULL
abnormality	NULL
and	NULL
the	NULL
clinical	NULL
abnormalities	NULL
of	NULL
the	NULL
index	NULL
subject	NULL
(	NULL
9	NULL
)	NULL
.	NULL

First	NULL
,	NULL
cortisol	NULL
,	NULL
the	NULL
naturally	NULL
occurring	NULL
glucocorticoid	NULL
,	NULL
may	NULL
bind	NULL
less	NULL
effectively	NULL
to	NULL
the	NULL
mutant	NULL
receptor	NULL
than	NULL
dexamethasone	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
mutant	NULL
receptor	NULL
may	NULL
have	NULL
more	NULL
abnormal	NULL
functions	NULL
than	NULL
just	NULL
ligand	NULL
binding	NULL
.	NULL

These	NULL
possibilities	NULL
are	NULL
not	NULL
mutually	NULL
exclusive	NULL
,	NULL
and	NULL
there	NULL
is	NULL
some	NULL
evidence	NULL
for	NULL
both	NULL
.	NULL

The	NULL
ratio	NULL
of	NULL
dissociation	NULL
constants	NULL
of	NULL
the	NULL
mutant	NULL
receptor	NULL
to	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
receptor	NULL
is	NULL
1.9	NULL
for	NULL
dexamethasone	NULL
and	NULL
2.9	NULL
for	NULL
cortisol	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
natural	NULL
ligand	NULL
is	NULL
affected	NULL
to	NULL
a	NULL
greater	NULL
degree	NULL
than	NULL
binding	NULL
of	NULL
dexamethasone	NULL
,	NULL
a	NULL
more	NULL
potent	NULL
glucocorticoid	NULL
agonist	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
dexamethasone-binding	NULL
studies	NULL
may	NULL
not	NULL
accurately	NULL
predict	NULL
the	NULL
magnitude	NULL
of	NULL
the	NULL
clinical	NULL
abnormalities	NULL
,	NULL
since	NULL
cortisol	NULL
is	NULL
the	NULL
naturally	NULL
occurring	NULL
glucocorticoid	NULL
.	NULL

It	NULL
should	NULL
also	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
valine	NULL
at	NULL
amino	NULL
acid	NULL
position	NULL
729	NULL
is	NULL
present	NULL
1924	NULL
throughout	NULL
evolution	NULL
.	NULL

Mouse	NULL
(	NULL
13	NULL
)	NULL
,	NULL
rat	NULL
(	NULL
33	NULL
)	NULL
,	NULL
and	NULL
new	NULL
world	NULL
monkey	NULL
(	NULL
34	NULL
)	NULL
glucocorticoid	NULL
receptors	NULL
all	NULL
normally	NULL
contain	NULL
a	NULL
valine	NULL
at	NULL
the	NULL
position	NULL
equivalent	NULL
to	NULL
residue	NULL
729	NULL
of	NULL
the	NULL
human	NULL
receptor	NULL
.	NULL

Thus	NULL
,	NULL
this	NULL
amino	NULL
acid	NULL
may	NULL
serve	NULL
a	NULL
key	NULL
function	NULL
in	NULL
the	NULL
mechanism	NULL
of	NULL
hGR	NULL
action	NULL
.	NULL

Isoleucine	NULL
has	NULL
a	NULL
slightly	NULL
more	NULL
bulky	NULL
side	NULL
chain	NULL
than	NULL
valine	NULL
,	NULL
and	NULL
this	NULL
may	NULL
hinder	NULL
glucocorticoid	NULL
binding	NULL
to	NULL
the	NULL
receptor	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
suggested	NULL
that	NULL
this	NULL
region	NULL
of	NULL
the	NULL
hGR	NULL
may	NULL
be	NULL
important	NULL
in	NULL
receptor	NULL
dimerization	NULL
,	NULL
which	NULL
may	NULL
promote	NULL
hGR	NULL
binding	NULL
to	NULL
the	NULL
glucocorticoid	NULL
regulatory	NULL
elements	NULL
(	NULL
35	NULL
)	NULL
.	NULL

This	NULL
mutation	NULL
may	NULL
interfere	NULL
with	NULL
dimerization	NULL
,	NULL
thereby	NULL
inhibiting	NULL
binding	NULL
of	NULL
the	NULL
activated	NULL
receptor	NULL
to	NULL
the	NULL
DNA	NULL
and	NULL
contributing	NULL
further	NULL
to	NULL
the	NULL
clinical	NULL
expression	NULL
of	NULL
cortisol	NULL
resistance	NULL
.	NULL

It	NULL
is	NULL
attractive	NULL
to	NULL
hypothesize	NULL
that	NULL
this	NULL
amino	NULL
acid	NULL
is	NULL
bifunctional	NULL
,	NULL
since	NULL
this	NULL
may	NULL
help	NULL
to	NULL
explain	NULL
the	NULL
apparent	NULL
discrepancy	NULL
between	NULL
alterations	NULL
in	NULL
binding	NULL
affinity	NULL
of	NULL
dexamethasone	NULL
and	NULL
the	NULL
apparent	NULL
potency	NULL
of	NULL
dexamethasone	NULL
to	NULL
stimulate	NULL
gene	NULL
transcription	NULL
;	NULL
the	NULL
former	NULL
is	NULL
altered	NULL
twofold	NULL
whereas	NULL
the	NULL
latter	NULL
is	NULL
altered	NULL
fourfold	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
here	NULL
do	NULL
not	NULL
explain	NULL
why	NULL
the	NULL
dissociation	NULL
constant	NULL
of	NULL
the	NULL
MNL	NULL
hGR	NULL
from	NULL
both	NULL
the	NULL
index	NULL
subject	NULL
and	NULL
his	NULL
mother	NULL
are	NULL
equal	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
binding	NULL
assay	NULL
is	NULL
not	NULL
sensitive	NULL
enough	NULL
to	NULL
detect	NULL
subtle	NULL
differences	NULL
.	NULL

If	NULL
the	NULL
mutant	NULL
and	NULL
wild-type	NULL
hGR	NULL
bind	NULL
independently	NULL
,	NULL
then	NULL
a	NULL
slightly	NULL
curved	NULL
Scatchard	NULL
analysis	NULL
is	NULL
predicted	NULL
.	NULL

However	NULL
,	NULL
our	NULL
visual	NULL
analysis	NULL
of	NULL
the	NULL
predicted	NULL
Scatchard	NULL
curve	NULL
indicates	NULL
that	NULL
,	NULL
with	NULL
the	NULL
sensitivity	NULL
of	NULL
the	NULL
current	NULL
binding	NULL
assay	NULL
,	NULL
such	NULL
a	NULL
curve	NULL
would	NULL
be	NULL
impossible	NULL
to	NULL
distinguished	NULL
from	NULL
a	NULL
straight	NULL
line	NULL
.	NULL

Alternatively	NULL
,	NULL
there	NULL
may	NULL
be	NULL
unexpected	NULL
interactions	NULL
between	NULL
receptors	NULL
that	NULL
influences	NULL
their	NULL
apparent	NULL
binding	NULL
affinities	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
an	NULL
inherited	NULL
point	NULL
missense	NULL
mutation	NULL
of	NULL
the	NULL
hGR	NULL
glucocorticoid-binding	NULL
domain	NULL
in	NULL
a	NULL
subject	NULL
with	NULL
primary	NULL
cortisol	NULL
resistance	NULL
.	NULL

This	NULL
mutation	NULL
was	NULL
identified	NULL
by	NULL
sequencing	NULL
cDNA	NULL
prepared	NULL
from	NULL
mRNA	NULL
and	NULL
was	NULL
subsequently	NULL
demonstrated	NULL
to	NULL
be	NULL
present	NULL
in	NULL
genomic	NULL
DNA	NULL
.	NULL

This	NULL
conservative	NULL
mutation	NULL
decreases	NULL
the	NULL
affinity	NULL
of	NULL
the	NULL
expressed	NULL
glucocorticoid	NULL
receptor	NULL
for	NULL
glucocorticoids	NULL
and	NULL
impairs	NULL
its	NULL
ability	NULL
to	NULL
stimulate	NULL
gene	NULL
transcription	NULL
.	NULL

The	NULL
magnitude	NULL
of	NULL
the	NULL
changes	NULL
observed	NULL
in	NULL
vitro	NULL
in	NULL
these	NULL
studies	NULL
are	NULL
very	NULL
similar	NULL
to	NULL
the	NULL
magnitude	NULL
of	NULL
the	NULL
changes	NULL
observed	NULL
previously	NULL
in	NULL
the	NULL
patient	NULL
.	NULL

Taken	NULL
together	NULL
these	NULL
results	NULL
strongly	NULL
support	NULL
the	NULL
hypothesis	NULL
that	NULL
homozygosity	NULL
for	NULL
this	NULL
mutation	NULL
causes	NULL
the	NULL
clinical	NULL
and	NULL
biochemical	NULL
phenotype	NULL
of	NULL
primary	NULL
cortisol	NULL
resistance	NULL
in	NULL
the	NULL
kindred	NULL
under	NULL
study	NULL
.	NULL

These	NULL
studies	NULL
also	NULL
suggest	NULL
that	NULL
Val	NULL
729	NULL
of	NULL
the	NULL
hGR	NULL
is	NULL
critical	NULL
for	NULL
its	NULL
normal	NULL
function	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Drs	NULL
.	NULL

Robert	NULL
M.	NULL
Carey	NULL
,	NULL
Alan	NULL
Rogol	NULL
,	NULL
Lawrence	NULL
G.	NULL
Raisz	NULL
,	NULL
Mary	NULL
Louise	NULL
Stover	NULL
,	NULL
David	NULL
Brandon	NULL
,	NULL
and	NULL
D.	NULL
Lynn	NULL
Loriaux	NULL
for	NULL
their	NULL
encouragement	NULL
and	NULL
helpful	NULL
comments	NULL
and	NULL
Ms.	NULL
Patricia	NULL
Hart	NULL
and	NULL
Mr.	NULL
Jonathan	NULL
Korn	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

Supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
University	NULL
of	NULL
Connecticut	NULL
Clinical	NULL
Research	NULL
Center	NULL
,	NULL
the	NULL
University	NULL
of	NULL
Connecticut	NULL
Health	NULL
Center	NULL
Research	NULL
Foundation	NULL
,	NULL
and	NULL
the	NULL
Diabetes	NULL
Research	NULL
and	NULL
Education	NULL
Foundation	NULL
,	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grant	NULL
IR29DK	NULL
42840-01	NULL
.	NULL

C.	NULL
H.	NULL
Bergh	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
travel	NULL
grant	NULL
award	NULL
from	NULL
the	NULL
Swedish	NULL
Medical	NULL
Research	NULL
Council	NULL
,	NULL
the	NULL
Swedish	NULL
National	NULL
Association	NULL
against	NULL
Heart	NULL
and	NULL
Chest	NULL
Diseases	NULL
,	NULL
and	NULL
the	NULL
Swedish	NULL
Society	NULL
of	NULL
Endocrinology	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Vingerhoeds	NULL
,	NULL
A.	NULL
C.	NULL
M.	NULL
,	NULL
J.	NULL
H.	NULL
H.	NULL
Thijssen	NULL
,	NULL
and	NULL
F.	NULL
Schwarz	NULL
.	NULL

1976	NULL
.	NULL

Spontane-	NULL
ous	NULL
hypercortisolism	NULL
without	NULL
Cushing	NULL
's	NULL
syndrome	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

43:1128-1133	NULL
.	NULL

Malchoff	NULL
,	NULL
Brufsky	NULL
,	NULL
Reardon	NULL
,	NULL
McDermott	NULL
,	NULL
Javier	NULL
,	NULL
Bergh	NULL
,	NULL
Rowe	NULL
,	NULL
and	NULL
Malchoff	NULL
2	NULL
.	NULL

Chrousos	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
A.	NULL
C.	NULL
M.	NULL
Vingerhoeds	NULL
,	NULL
D.	NULL
Brandon	NULL
,	NULL
C.	NULL
Eil	NULL
,	NULL
M.	NULL
Pugeat	NULL
,	NULL
M.	NULL
DeVroede	NULL
,	NULL
D.	NULL
L.	NULL
Loriaux	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Lipsett	NULL
.	NULL

1982	NULL
.	NULL

Primary	NULL
cortisol	NULL
resistance	NULL
in	NULL
man	NULL
.	NULL

A	NULL
glucocorticoid	NULL
receptor	NULL
mediated	NULL
disease	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

69:1261-1269	NULL
.	NULL

3	NULL
.	NULL

Chrousos	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
A.	NULL
C.	NULL
M.	NULL
Vingerhoeds	NULL
,	NULL
D.	NULL
L.	NULL
Loriaux	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Lipsett	NULL
.	NULL

1983	NULL
.	NULL

Primary	NULL
cortisol	NULL
resistance	NULL
:	NULL
a	NULL
family	NULL
study	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

56:1243-1245	NULL
.	NULL

4.	NULL
lida	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Gomi	NULL
,	NULL
K.	NULL
Moriwaki	NULL
,	NULL
Y.	NULL
Itoh	NULL
,	NULL
K.	NULL
Hirobe	NULL
,	NULL
Y.	NULL
Matsuzawa	NULL
,	NULL
S.	NULL
Katagiri	NULL
,	NULL
T.	NULL
Yonezawa	NULL
,	NULL
and	NULL
S.	NULL
Tarui	NULL
.	NULL

1985	NULL
.	NULL

Primary	NULL
cortisol	NULL
resistance	NULL
accompanied	NULL
by	NULL
a	NULL
reduction	NULL
in	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
two	NULL
members	NULL
of	NULL
the	NULL
same	NULL
family	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

60:967-971	NULL
.	NULL

5	NULL
.	NULL

Nawata	NULL
,	NULL
H.	NULL
,	NULL
K.	NULL
Sekiya	NULL
,	NULL
K.	NULL
Higuchi	NULL
,	NULL
K.	NULL
Kato	NULL
,	NULL
and	NULL
H.	NULL
Ibayashi	NULL
.	NULL

1987	NULL
.	NULL

Decreased	NULL
deoxyribonucleic	NULL
acid	NULL
binding	NULL
of	NULL
a	NULL
glucocorticoid-receptor	NULL
complex	NULL
in	NULL
cultured	NULL
skin	NULL
fibroblasts	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
glucocorticoid	NULL
resistance	NULL
syndrome	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

65:219-226	NULL
.	NULL

6	NULL
.	NULL

Bronnegard	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Werner	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Gustaffson	NULL
.	NULL

1986	NULL
.	NULL

Primary	NULL
cortisol	NULL
resistance	NULL
associated	NULL
with	NULL
a	NULL
thermolabile	NULL
receptor	NULL
in	NULL
a	NULL
patient	NULL
with	NULL
fatigue	NULL
as	NULL
the	NULL
only	NULL
symptom	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

78:1270-1278	NULL
.	NULL

7	NULL
.	NULL

Lamberts	NULL
,	NULL
S.	NULL
W.	NULL
J.	NULL
,	NULL
D.	NULL
Polderman	NULL
,	NULL
M.	NULL
Zweens	NULL
,	NULL
and	NULL
F.	NULL
H.	NULL
de	NULL
Jong	NULL
.	NULL

1986	NULL
.	NULL

Familial	NULL
cortisol	NULL
resistance	NULL
:	NULL
differential	NULL
diagnostic	NULL
and	NULL
therapeutic	NULL
aspects	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

63:1328-1	NULL
333	NULL
.	NULL

8	NULL
.	NULL

Gomi	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Iida	NULL
,	NULL
M.	NULL
Tsugawa	NULL
,	NULL
Y.	NULL
Itoh	NULL
,	NULL
K.	NULL
Moriawaki	NULL
,	NULL
and	NULL
S.	NULL
Yamashita	NULL
.	NULL

1986	NULL
.	NULL

Decreased	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
cultured	NULL
skin	NULL
fibroblasts	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
primary	NULL
cortisol	NULL
resistance	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

314:1194	NULL
.	NULL

9	NULL
.	NULL

Maichoff	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
E.	NULL
C.	NULL
Javier	NULL
,	NULL
D.	NULL
M.	NULL
Malchoff	NULL
,	NULL
T.	NULL
Martin	NULL
,	NULL
A.	NULL
Rogol	NULL
,	NULL
D.	NULL
Brandon	NULL
,	NULL
D.	NULL
L.	NULL
Loriaux	NULL
,	NULL
and	NULL
G.	NULL
E.	NULL
Reardon	NULL
.	NULL

1990	NULL
.	NULL

Primary	NULL
cortisol	NULL
resistance	NULL
presenting	NULL
as	NULL
isosexual	NULL
precocity	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

70:503-507	NULL
.	NULL

10	NULL
.	NULL

Lamberts	NULL
,	NULL
S.	NULL
W.	NULL
J.	NULL
,	NULL
J.	NULL
W.	NULL
Koper	NULL
,	NULL
P.	NULL
Biemond	NULL
,	NULL
F.	NULL
H.	NULL
den	NULL
Holder	NULL
,	NULL
and	NULL
F.	NULL
H.	NULL
de	NULL
Jong	NULL
.	NULL

1992	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

74:313-321	NULL
.	NULL

11	NULL
.	NULL

Hurley	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
D.	NULL
Accili	NULL
,	NULL
C.	NULL
Stratakis	NULL
,	NULL
M.	NULL
Karl	NULL
,	NULL
N.	NULL
Vamvakopoilos	NULL
,	NULL
E.	NULL
Rorer	NULL
,	NULL
K.	NULL
Constantine	NULL
,	NULL
S.	NULL
I.	NULL
Taylor	NULL
,	NULL
and	NULL
G.	NULL
P.	NULL
Chrousos	NULL
.	NULL

1991	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
gene	NULL
in	NULL
familial	NULL
glucocorticoid	NULL
resistance	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

87:680-686	NULL
.	NULL

12	NULL
.	NULL

Caristedt-Duke	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
E.	NULL
Stromstedt	NULL
,	NULL
O.	NULL
Wrange	NULL
,	NULL
T.	NULL
Bergman	NULL
,	NULL
J.	NULL
Gustafsson	NULL
,	NULL
and	NULL
H.	NULL
Jornvall	NULL
.	NULL

1987	NULL
.	NULL

Domain	NULL
structure	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
protein	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

84:4437-4440	NULL
.	NULL

13	NULL
.	NULL

Danielsen	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
P.	NULL
Northrup	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Ringold	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
mouse	NULL
glucocorticoid	NULL
receptor	NULL
:	NULL
mapping	NULL
of	NULL
functional	NULL
domains	NULL
by	NULL
cloning	NULL
,	NULL
sequencing	NULL
and	NULL
expression	NULL
of	NULL
wild-type	NULL
and	NULL
mutant	NULL
receptor	NULL
proteins	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

5:2513-2522	NULL
.	NULL

14	NULL
.	NULL

Evans	NULL
,	NULL
R.	NULL
1988	NULL
.	NULL

The	NULL
steroid	NULL
and	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
superfamily	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

240:889-895	NULL
.	NULL

15	NULL
.	NULL

Giguere	NULL
,	NULL
V.	NULL
,	NULL
S.	NULL
M.	NULL
Hollenberg	NULL
,	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1986	NULL
.	NULL

Functional	NULL
domains	NULL
of	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Cell	NULL
.	NULL

46:645-652	NULL
.	NULL

16	NULL
.	NULL

Rusconi	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
K.	NULL
Yamamoto	NULL
.	NULL

1987	NULL
.	NULL

Functional	NULL
dissection	NULL
of	NULL
the	NULL
hormone	NULL
and	NULL
DNA	NULL
binding	NULL
activities	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

61309-1315	NULL
.	NULL

17	NULL
.	NULL

Chomczynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
N.	NULL
Saachi	NULL
.	NULL

1987	NULL
.	NULL

Single-step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
guanidinium-thiocyanate-phenol-chloroform	NULL
extraction	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162:1569-1571	NULL
.	NULL

18	NULL
.	NULL

D'Alessio	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
M.	NULL
C.	NULL
Noon	NULL
,	NULL
H.	NULL
L.	NULL
Ley	NULL
,	NULL
and	NULL
G.	NULL
F.	NULL
Girard	NULL
.	NULL

1987	NULL
.	NULL

One-tube	NULL
double	NULL
stranded	NULL
cDNA	NULL
synthesis	NULL
using	NULL
cloned	NULL
MMuLV	NULL
reverse	NULL
transcriptase	NULL
.	NULL

BRL	NULL
Focus	NULL
.	NULL

9:1-4	NULL
.	NULL

19	NULL
.	NULL

Hollenberg	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
C.	NULL
Weinberger	NULL
,	NULL
E.	NULL
S.	NULL
Ong	NULL
,	NULL
G.	NULL
Cerelli	NULL
,	NULL
A.	NULL
Oro	NULL
,	NULL
R.	NULL
Lebo	NULL
,	NULL
E.	NULL
B.	NULL
Thompson	NULL
,	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1985	NULL
.	NULL

Primary	NULL
structure	NULL
and	NULL
expression	NULL
of	NULL
a	NULL
functional	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
cDNA	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

318:635-641	NULL
.	NULL

20	NULL
.	NULL

Saiki	NULL
,	NULL
R.	NULL
K.	NULL
,	NULL
D.	NULL
H.	NULL
Gelfand	NULL
,	NULL
S.	NULL
Stoffel	NULL
,	NULL
S.	NULL
J.	NULL
Scharf	NULL
,	NULL
R.	NULL
Higuchi	NULL
,	NULL
G.	NULL
T.	NULL
Horn	NULL
,	NULL
K.	NULL
B.	NULL
Mullis	NULL
,	NULL
and	NULL
H.	NULL
A.	NULL
Erlich	NULL
.	NULL

1988	NULL
.	NULL

Primer-directed	NULL
enzymatic	NULL
amplification	NULL
of	NULL
DNA	NULL
with	NULL
a	NULL
thermostable	NULL
DNA	NULL
polymerase	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

239:487-491	NULL
.	NULL

21	NULL
.	NULL

Maniatis	NULL
,	NULL
T.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
J.	NULL
Sambrook	NULL
.	NULL

1982	NULL
.	NULL

Polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

/n	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
.	NULL

173-177	NULL
.	NULL

22	NULL
.	NULL

Eckert	NULL
,	NULL
R.	NULL
I	NULL
.	NULL

1989	NULL
.	NULL

DNA	NULL
Sequencing	NULL
.	NULL

In	NULL
Current	NULL
Protocols	NULL
in	NULL
Molecular	NULL
Biology	NULL
.	NULL

F.	NULL
M.	NULL
Ansubel	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
,	NULL
editors	NULL
.	NULL

Wiley	NULL
Interscience	NULL
,	NULL
New	NULL
York	NULL
.	NULL

7.1.1-7.6.5	NULL
.	NULL

23	NULL
.	NULL

Gross-Bellard	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
Oudet	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1973	NULL
.	NULL

Isolation	NULL
of	NULL
high-molecular-weight	NULL
DNA	NULL
from	NULL
mammalian	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

36:32-38	NULL
.	NULL

24	NULL
.	NULL

Encio	NULL
,	NULL
I.	NULL
J.	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Detera-Wadleigh	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
genomic	NULL
structure	NULL
of	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

J.	NULL
Bio/	NULL
.	NULL

Chem	NULL
.	NULL

266:7182-7188	NULL
.	NULL

25	NULL
.	NULL

Eastman	NULL
,	NULL
A	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
improvement	NULL
to	NULL
the	NULL
novel	NULL
rapid	NULL
assay	NULL
of	NULL
chloramphenicol	NULL
acetyl	NULL
transferase	NULL
gene	NULL
expression	NULL
.	NULL

Biotechniques	NULL
.	NULL

5:730	NULL
.	NULL

26	NULL
.	NULL

Noma	NULL
,	NULL
K.	NULL
,	NULL
D.	NULL
Nakao	NULL
,	NULL
B.	NULL
Sato	NULL
,	NULL
Y.	NULL
Nishizawa	NULL
,	NULL
K.	NULL
Matsumoto	NULL
,	NULL
and	NULL
Y.	NULL
Yamamura	NULL
.	NULL

1980	NULL
.	NULL

Effect	NULL
of	NULL
molybdate	NULL
on	NULL
activation	NULL
and	NULL
stabilization	NULL
of	NULL
steroid	NULL
receptors	NULL
.	NULL

Endocrinology	NULL
.	NULL

107:1205-1211	NULL
.	NULL

27	NULL
.	NULL

Cheng	NULL
,	NULL
V.	NULL
C.	NULL
,	NULL
and	NULL
Prusoff	NULL
,	NULL
W.	NULL
H.	NULL
1973	NULL
.	NULL

Relationship	NULL
between	NULL
the	NULL
inhibition	NULL
constant	NULL
and	NULL
the	NULL
concentration	NULL
of	NULL
inhibitor	NULL
which	NULL
causes	NULL
50	NULL
per	NULL
cent	NULL
inhibition	NULL
of	NULL
an	NULL
enzymatic	NULL
reaction	NULL
.	NULL

Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

22:3099-3108	NULL
.	NULL

28	NULL
.	NULL

Picard	NULL
,	NULL
D.	NULL
,	NULL
S.	NULL
J.	NULL
Salser	NULL
,	NULL
and	NULL
K.	NULL
Yamamoto	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
movable	NULL
and	NULL
regulable	NULL
inactivation	NULL
function	NULL
within	NULL
the	NULL
steroid	NULL
binding	NULL
region	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Cell	NULL
.	NULL

54:1073-1080	NULL
.	NULL

29	NULL
.	NULL

Lubahn	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
T.	NULL
R.	NULL
Brown	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Simental	NULL
,	NULL
H.	NULL
N.	NULL
Higgs	NULL
,	NULL
C.	NULL
J.	NULL
Migeon	NULL
,	NULL
E.	NULL
M.	NULL
Wilson	NULL
,	NULL
and	NULL
F.	NULL
S.	NULL
French	NULL
.	NULL

1989	NULL
.	NULL

Sequence	NULL
of	NULL
the	NULL
intron/exon	NULL
junctions	NULL
of	NULL
the	NULL
coding	NULL
region	NULL
of	NULL
the	NULL
human	NULL
androgen	NULL
receptor	NULL
gene	NULL
and	NULL
identification	NULL
of	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
a	NULL
family	NULL
with	NULL
complete	NULL
androgen	NULL
insensitivity	NULL
.	NULL

Proc	NULL
.	NULL

Nat/	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:9534-9538	NULL
.	NULL

30	NULL
.	NULL

Usala	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
G.	NULL
E.	NULL
Tennyson	NULL
,	NULL
A.	NULL
E.	NULL
Bale	NULL
,	NULL
R.	NULL
W.	NULL
Lash	NULL
,	NULL
N.	NULL
Gesundheit	NULL
,	NULL
F.	NULL
E.	NULL
Wondisford	NULL
,	NULL
D.	NULL
Accili	NULL
,	NULL
P.	NULL
Hauser	NULL
,	NULL
and	NULL
B.	NULL
D.	NULL
Weintraub	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
base	NULL
mutation	NULL
of	NULL
the	NULL
C-erbA8	NULL
thyroid	NULL
hormone	NULL
receptor	NULL
in	NULL
a	NULL
kindred	NULL
with	NULL
generalized	NULL
thyroid	NULL
hormone	NULL
resistance	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

85:93-100	NULL
.	NULL

31	NULL
.	NULL

McPhaul	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
M.	NULL
Marcelli	NULL
,	NULL
S.	NULL
Zoppi	NULL
,	NULL
J.	NULL
E.	NULL
Griffin	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Wilson	NULL
.	NULL

1992	NULL
.	NULL

Amino	NULL
acid	NULL
substitutions	NULL
that	NULL
cause	NULL
androgen	NULL
resistance	NULL
cluster	NULL
in	NULL
short	NULL
segments	NULL
of	NULL
the	NULL
androgen	NULL
receptor	NULL
gene	NULL
.	NULL

Cin	NULL
.	NULL

Res	NULL
.	NULL

40:251a	NULL
.	NULL

(	NULL
Abstr	NULL
.	NULL
)	NULL

32	NULL
.	NULL

Javier	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
G.	NULL
E.	NULL
Reardon	NULL
,	NULL
and	NULL
C.	NULL
D.	NULL
Malchoff	NULL
.	NULL

1991	NULL
.	NULL

Glucocorticoid	NULL
resistance	NULL
and	NULL
its	NULL
clinical	NULL
presentations	NULL
.	NULL

The	NULL
Endocrinologist	NULL
.	NULL

1:141-148	NULL
.	NULL

33	NULL
.	NULL

Miesfield	NULL
,	NULL
R.	NULL
,	NULL
S.	NULL
Rusconi	NULL
,	NULL
P.	NULL
J.	NULL
Godowski	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Maler	NULL
,	NULL
S.	NULL
Okret	NULL
,	NULL
A.	NULL
Wilkstrom	NULL
,	NULL
J.	NULL
Gustafsson	NULL
,	NULL
and	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
.	NULL

1986	NULL
.	NULL

Genetic	NULL
complementa-tion	NULL
of	NULL
a	NULL
glucocorticoid	NULL
receptor	NULL
deficiency	NULL
by	NULL
expression	NULL
of	NULL
cloned	NULL
receptor	NULL
cDNA	NULL
.	NULL

Cell	NULL
.	NULL

46:389-399	NULL
.	NULL

34	NULL
.	NULL

Brandon	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
A.	NULL
J.	NULL
Markwick	NULL
,	NULL
and	NULL
D.	NULL
L.	NULL
Loriaux	NULL
,	NULL
D.	NULL
L.	NULL
1989	NULL
.	NULL

Alterations	NULL
in	NULL
the	NULL
functional	NULL
domains	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
gene	NULL
from	NULL
a	NULL
glucocorticoid	NULL
``	NULL
resistant	NULL
``	NULL
new	NULL
world	NULL
primate	NULL
.	NULL

Endocr	NULL
.	NULL

Soc	NULL
.	NULL

71st	NULL
Annu	NULL
.	NULL

Meet	NULL
.	NULL

1375a	NULL
.	NULL

(	NULL
Abstr	NULL
.	NULL
)	NULL

35	NULL
.	NULL

Fawell	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Lees	NULL
,	NULL
R.	NULL
White	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Parker	NULL
.	NULL

1990	NULL
.	NULL

Characterization	NULL
and	NULL
colocalization	NULL
of	NULL
steroid	NULL
binding	NULL
and	NULL
dimerization	NULL
activities	NULL
in	NULL
the	NULL
mouse	NULL
estrogen	NULL
receptor	NULL
.	NULL

Cell	NULL
.	NULL

60:953-960	NULL
.	NULL

Glucocorticoid	NULL
Receptor	NULL
Mutation	NULL
__	NULL
1925	NULL

